Batf3-Deficient Mice: Susceptibility to Toxoplasma gondii and Responses to IL-12 Treatment in vivo by Mashayekhi, Mona
Washington University in St. Louis
Washington University Open Scholarship
All Theses and Dissertations (ETDs)
Spring 3-4-2013
Batf3-Deficient Mice: Susceptibility to Toxoplasma
gondii and Responses to IL-12 Treatment in vivo
Mona Mashayekhi
Washington University in St. Louis
Follow this and additional works at: https://openscholarship.wustl.edu/etd
Part of the Immunology and Infectious Disease Commons
This Dissertation is brought to you for free and open access by Washington University Open Scholarship. It has been accepted for inclusion in All
Theses and Dissertations (ETDs) by an authorized administrator of Washington University Open Scholarship. For more information, please contact
digital@wumail.wustl.edu.
Recommended Citation
Mashayekhi, Mona, "Batf3-Deficient Mice: Susceptibility to Toxoplasma gondii and Responses to IL-12 Treatment in vivo" (2013). All
Theses and Dissertations (ETDs). 1054.
https://openscholarship.wustl.edu/etd/1054
WASHINGTON UNIVERSITY IN ST. LOUIS 
Division of Biology and Biomedical Sciences 
Immunology 
 
 
Dissertation Examination Committee: 
Kenneth Murphy, Chair 
Brian Edelson 
Robert Schreiber 
Laurence Sibley 
Herbert Virgin 
Wayne Yokoyama 
 
Batf3-Deficient Mice: Susceptibility to Toxoplasma gondii and Responses to IL-12 
Treatment in vivo 
by 
Mona Mashayekhi 
 
A dissertation presented to the 
Graduate School of Arts and Sciences 
of Washington University in 
partial fulfillment of the 
requirements for the degree 
of Doctor of Philosophy 
 
 
 
May 2013 
St. Louis, Missouri
 ii 
TABLE OF CONTENTS 
PAGE 
List of Figures         iii 
List of Abbreviations         vii 
Acknowledgements        x 
Abstract         xii 
Chapter 1:  Introduction       1 
Chapter 2:  Experimental Procedures     16 
Chapter 3:  Batf3-/- Mice are Highly Susceptible to T. gondii Infection 27 
Chapter 4:  CD8α+ DCs are Required for CD8+ T Cell Priming to  31 
Endogenous T. gondii Antigens 
Chapter 5: IL-12 Production by CD8α+ DCs is Required for   36 
  Protection Against Acute T. gondii Infection 
Chapter 6: IL-12 Bypasses the Block in CD8α+ DC Development in 55 
  Batf3-/- Mice 
Chapter 7:  Discussion       91 
References         96 
 
 
 
 
 
 
 iii 
LIST OF FIGURES 
CHAPTER 3           
Figure 1: Batf3-/- mice rapidly succumb to infection with an avirulent strain of 
Toxoplasma gondii.  
Figure 2: Batf3-/- mice are highly susceptible to oral infection with T. gondii cysts 
and cannot control parasite replication.  
CHAPTER 4 
Figure 3: CD8+ T cell priming to T. gondii is defective in Batf3-deficient mice.  
Figure 4: CD8+ T cell compartment is normal in Batf3-/- mice.  
Figure 5: The presence of wild-type T cells in Batf3-/- mice does not change their 
susceptibility to T. gondii infection.  
CHAPTER 5 
Figure 6: Batf3-/- mice have reduced serum IL-12 and IFNγ during Toxoplasma 
gondii infection.  
Figure 7: Splenic CD8α+ dendritic cells expand after T. gondii infection in wild-
type mice. 
Figure 8: CD11b+ DC percentages or numbers do not change during T. gondii 
infection.  
Figure 9: CD8α+ dendritic cells are the major producers of IL-12 after T. gondii 
infection in wild-type mice  
Figure 10: Neutrophils, inflammatory monocytes and plasmacytoid DCs do not 
produce IL-12p40 upon T. gondii infection.  
 iv 
Figure 11: CD8α+ DCs express the highest level of the T. gondii sensor TLR11.  
Figure 12: CD8α+ DCs produce IL-12, but not IL-23, in response to T. gondii 
infection. 
Figure 13: Administration of IL-12 rescues Batf3-deficient mice during T. gondii 
infection.  
Figure 14: Batf3-/- NK cells can produce IFNγ in vitro in response to IL-12 and IL-18.  
Figure 15: Administration of IL-12 restores IFNγ production in Batf3-deficient mice 
during T. gondii infection.  
Figure 16: CD8α+ dendritic cells are the only cells whose IL-12 production is 
protective against acute T. gondii infection.  
Figure 17: Mice re-constituted with a 1:1 mixture of Batf3-/- plus IL-12p35-/- bone 
marrow are unable to control T. gondii burden.  
CHAPTER 6 
Figure 18: IL-12 administration rescues CD8α+ DC development in infected Batf3-/- 
mice. 
Figure 19: IL-12 treatment restores CD8α+ DC development in Batf3-/- mice.  
Figure 20: CD8α+ DCs in the spleen of IL-12-treated Batf3-/- mice do not express the 
B cells marker B220, the T cell marker CD3, or the NK cell marker 
NKp46.  
Figure 21: Mice deficient in IL-12 can develop splenic CD8α+ DCs in the steady 
state. 
Figure 22: IL-12-mediated restoration of CD8α+ DCs in Batf3-/- mice is IFNγ-
 v 
dependent.  
Figure 23: Efficiency of NK cell depletion using anti-NK1.1 PK136 antibody.  
Figure 24: IL-12 can restore CD8α+ DCs in Batf3-/- mice in the absence of B, T and 
NK cells.  
Figure 25: Time course of CD8α+ DC development in IL-12-treated Batf3-/- mice.  
Figure 26: Pre-cDC numbers in the spleen are unchanged with IL-12 treatment.  
Figure 27: IL-12 treatment causes upregulation of DEC205 on CD8α+ DC precursors 
in both wild-type and Batf3-/- mice.  
Figure 28: Batf3-/- IL-12-restored CD8α+ DCs express normal levels of the 
transcription factors Batf and IRF-8.  
Figure 29: M plots comparing gene expression of IL-12-restored CD8α+ DCs. 
Figure 30: T. gondii infection restores CD8α+ DC development in Batf3-/- mice.  
Figure 31: T. gondii-mediated restoration of CD8α+ DCs in Batf3-/- mice is IFNγ-
dependent. 
Figure 32: IL-12p35-/- CD8α+ DCs increase in percentage, but not absolute numbers, 
after T. gondii infection.  
Figure 33: IL-12 treatment restores cross-presentation in Batf3-/- mice in vivo.  
Figure 34: In vivo cross-presentation of necrotic cell-associated antigen is severely 
impaired in Batf3-/- mice.  
Figure 35: IL-12-restored CD8α+ DCs in Batf3-/- mice produce IL-12 in response to 
T. gondii infection in vivo.  
 
 vi 
Figure 36: CD8+ T cell priming to T. gondii-derived antigen is restored in infected 
Batf3-/- mice given IL-12.  
 vii 
LIST OF ABBREVIATIONS 
AIDS   Acquired Immuno-Deficiency Syndrome 
AP-1   Activator Protein 1 
APC   Antigen Presenting Cell 
BATF   Basic Leucine Zipper Transcription Factor, ATF-like 
BM   Bone Marrow 
BMM   Bone Marrow-Derived Macrophages 
CCL   Chemokine (C-C motif) Ligand 
CCR   Chemokine (C-C motif) Receptor 
CD   Cluster of Differentiation 
cDC   Conventional Dendritic Cell 
CFDA-SE  Carboxy-Fluorescein diacetate Succinimyidyl Ester 
CFSE   Carboxy-Fluorescein Succinimyidyl Ester 
CLEC9A  C-Type Lectin Domain Family 9A 
CTL   Cytotoxic T Lymphocyte 
CX3CR1  CX3C Chemokine Receptor 1 
DC   Dendritic Cell 
DT   Diphtheria Toxin 
DTR   Diphtheria Toxin Receptor 
ER   Endoplasmic Reticulum 
FACS   Fluorescence Activated Cell Sorting 
Flt3L   Fms-related Tyrosine Kinase 3 Ligand 
 viii 
GCET2  Germinal Center B-Cell Expressed Transcript 2 
GFP   Green Fluorescence Protein 
GM-CSF  Granulocyte Macrophage Colony-Stimulating Factor 
ICS   Intracellular Cytokine Staining 
IDO   Indoleamine Dioxygenase 
IFNγ   Interferon gamma 
IL   Interleukin 
IL-12p35  IL-12 subunit p35 
IL-12p40  IL-12 subunit p40 
IL-12R  Interleukin 12 Receptor 
IL-23p19  IL-23 subunit p19 
iNOS   Inducible Nitric Oxide Synthase 
IP   Intraperitoenal 
IRF   Interferon Regulator Factor 
IRG   Immunity-Related GTPases 
IRGM3  Interferon-Gamma-Inducible GTPase 
IV   Intravenous 
L. monocytogenes Listeria monocytogenes 
LOD   Low Density 
LysM   Lysozyme M 
MHC   Major Histocompatibility Complex 
MHCI   Major Histocompatiblity Complex Class I 
 ix 
MHCII  Major Histocompatibility Complex Class II 
MyD88  Myeloid Differentation Primary Response Gene 88 
NF-κB   Nuclear Factor Kappa-B 
NK   Natural Killer 
NO   Nitric Oxide 
OVA   Ovalbumin 
pDC   Plasmacytoid Dendritic Cell 
PEC   Peritoneal Exudate Cell 
PRU   Prugniaud 
PV   Parasitophorous Vacuole 
RAG   Recombination Activating Gene 
RAC   Ras-Related C3 Botulinum Toxin Substrate 
SCID   Severe Combined Immunodeficiency 
SIRPα   Signal-Regulatory Protein Alpha 
STAg   Soluble Tachyzoite Antigen 
STAT   Signal Transducer and Activator of Transcription 
T. gondii  Toxoplasma gondii 
TAP   Transporter Associated with Antigen Processing 
Th1   T Helper Cell 1 
Th17   T Helper Cell 17 
TLR   Toll-like Receptor 
TNF   Tumor Necrosis Factor 
 x 
ACKNOWLEDGEMENTS 
 I would like to thank many people for their contribution to this work and to my 
development as a scientist. First and foremost, I would like to thank Ken Murphy for 
teaching me new ways to think and ask questions over the last four years. Ken’s ability to 
approach problems from various angles and overcome obstacles is awe-inspiring. I would 
also like to thank Theresa Murphy, who has been a second mentor and a friend, and is 
never frustrated by my daily barrage of questions. I would like to thank our collaborator 
David Sibley, who adopted me into his lab without hesitation, was extremely generous 
with reagents, and was an incredible mentor over the last two years. 
 I am extremely grateful for my colleagues in both the Murphy and the Sibley lab. 
They have inspired and supported me, and offered a helping hand or a shoulder to lean on 
throughout my graduate career. Michelle Sandau, Jennifer Gill, and Ellen Langer were 
always there to listen, give advice, critique, collaborate, and entertain me, and have truly 
made my time in lab memorable. I would also like to thank Brian Edelson, Wumesh KC, 
Ansu Satpathy, and Roxane Tussiwand for a number of collaborative efforts, without 
which this work would not have been completed. I would like to thank the entire Sibley 
lab for taking me in as one of their own, and helping me at every step along the way. I 
would especially like to thank Asis Khan for teaching me everything I know about 
Toxoplasma gondii.  
 In addition, I would like to thank my thesis committee for their continuous 
support and guidance: Dr. Wayne Yokoyama (Chair), Dr. Robert Schreiber, Dr. Herbert 
W. Virgin, Dr. Laurence David Sibley, Dr. Brian Edelson, and Dr. Deborah Lenschow.  
 xi 
I would also like to acknowledge the grants that funded this work: the National 
Research Science Award for the Medical Scientist through the NIH Institutional Research 
Training Grant, the Principles in Pulmonary Research Award through the NIH 
Institutional Research Training Grant, and the American Heart Association Midwest 
Affiliate Predoctoral Fellowship.  
 Finally, I would like to thank my friends and family for their continuing support 
through my endless graduate career: my mother, who always knows what to say; my best 
friend Nicole Maloney, who has been my companion and my other half throughout this 
journey; and my husband Gary, who puts up with me through my highs and lows and 
reminds me of the joys in life. 
 
 
 
 
 
 
 
 
 
 
 
 
 xii 
ABSTRACT OF THE DISSERTATION 
Batf3-Deficient Mice: Susceptibility to Toxoplasma gondii and Responses to IL-12 
Treatment in vivo 
by 
Mona Mashayekhi 
Doctor of Philosophy in Biology and Biomedical Sciences 
Immunology 
Washington University in St. Louis, 2013 
Professor Kenneth Murphy, Chairperson 
 
CD8α+ dendritic cells are important in vivo for cross-presentation of antigens 
derived from intracellular pathogens and tumors. Additionally, stimulation of IL-12 
production by CD8α+ DCs has suggested a role for these cells in response to Toxoplasma 
gondii antigens, although no experiments have yet shown an in vivo requirement for these 
cells against T. gondii infection. Towards this goal, we examined T. gondii infection of 
Batf3-/- mice, which selectively lack only lymphoid-resident CD8α+ DCs and related 
peripheral CD103+ DCs. Batf3-/- mice were extremely susceptible to T. gondii infection, 
with defective priming of CD8+ T cells, and decreased production of IL-12 and IFNγ. IL-
12 administration restored resistance in Batf3-/- mice, and mice in which IL-12 production 
was ablated only from CD8α+ DCs failed to control infection. These results reveal that 
the function of CD8α+ DCs extends beyond a role in cross-presentation and includes a 
critical role for activation of innate immunity through IL-12 production during T. gondii 
 xiii 
infection. 
While investigating the immune responses of Batf3-/- mice to T. gondii infection, 
we made the surprising discovery that IL-12 treatment of infected Batf3-/- mice resulted in 
re-appearance of the CD8α+ DC population in the spleen. In addition, we show that IL-
12-treatment alone in the absence of infection restored the CD8α+ DC population in 
Batf3-/- mice. Analysis of the restored cells by microarray revealed very few differences 
in gene expression between wild-type and IL-12-induced Batf3-/- CD8α+ DCs. 
Furthermore, IL-12 treatment of Batf3-/- mice restored their capacity for in vivo cross-
presentation of necrotic cell-associated antigens. Finally, the restored CD8α+ DCs primed 
CD8+ T cells against T. gondii-derived antigen, and produced IL-12 in vivo in response to 
T. gondii infection. Thus, IL-12 can induce development of CD8α+ DCs through a Batf3-
independent mechanism, and these cells can function to both prime T cells as well as 
produce IL-12 during infection in vivo. 
CHAPTER 1 
Introduction 
 
The innate immune response is the first line of defense against pathogens. Innate 
immune cells arrive first at the site of infection, limit immediate pathogen replication, 
and recruit other immune cells to mount an effective response. In addition, these cells 
have the crucial role of initiating and skewing the adaptive immune response, which is 
necessary in most cases for final elimination of the pathogen from the host. Dendritic 
cells (DCs) are antigen-presenting cells (APCs) of the innate immune system that serve 
the crucial function of activating T cells of the adaptive immune system.  
 
Antigen presentation 
The two main subsets of T cells, CD4+ and CD8+ T cells, are activated in different 
ways. CD8+ T cells are traditionally thought to respond to endogenous antigens within 
the cytosol, such as viral proteins in an infected cell. These antigens are presented by 
DCs via the major histocompatibility complex class I (MHCI) pathway, in which 
antigens from the cytoplasm are degraded by the proteosome and transported into the ER 
by the TAP1/2 proteins and chaperones. Within the ER, peptides are loaded onto MHCI, 
and the MHCI:peptide complex is transported to the plasma membrane for CD8+ T cell 
recognition. 
Exogenous antigens, on the other hand, are processed through the MHC class II 
(MHCII) pathway and presented to CD4+ T cells. In this pathway, exogenous antigens 
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such as extracellular bacteria are phagocytosed, sequentially processed within 
phagosomes into smaller peptide fragments, and loaded onto MHCII within the vesicle 
and transported to the surface. 
Cross-presentation is the process by which exogenous antigens are presented to 
CD8+ T cells on MHCI molecules. Although the precise mechanism is not yet known, 
cross-presentation is thought to require the transport of exogenous antigens from within 
phagosomes into the cytoplasm, followed by degradation of these antigens by the 
proteosome, and transport into the ER by TAP (Norbury et al., 1997; Vyas et al., 2008). 
Cross-presentation is thought to be important in inducing a robust CD8+ T cell response 
when endogenous antigens are not produced in the professional antigen presenting cells: 
DCs, macrophages, and B cells. Non-professional APCs are incapable of effectively 
priming CD8+ T cell responses. For example, viruses that do not directly invade and 
replicate in DCs fail to generate endogenous cytoplasmic antigens in these cells. Yet DCs 
are able to prime CD8+ T cell responses to such viruses by phagocytosis of dead cells 
containing virus particles, export of viral antigens from the phagosomes into the 
cytoplasm, followed by cross-presentation of these peptides on MHCI (Villadangos and 
Schnorrer, 2007). Similarly, cross-presentation is also necessary for CD8+ T cell priming 
to tumors (Huang et al., 1994). 
 
Dendritic cell subsets in the mouse 
Dendritic cells are the most efficient antigen presenting cells, and many DC 
subsets have now been described in both mice and humans, although the distinct 
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functions of these subsets are still under investigation. Mouse DCs in the spleen can be 
subdivided into two general groups, the plasmacytoid DCs (pDCs) and the conventional 
DCs (cDCs) (Satpathy et al., 2011). Plasmacytoid DCs express the cell surface markers 
CD11c, B220, Siglec-H and Bst2, and are thought to be important for the production of 
type I IFN during viral infection. Conventional DCs are currently divided into at least 
three subsets, namely CD8α+ DCs, CD4+ DCs, and double-negative DCs. Alternatively, 
the surface marker CD11b can be used to identify the CD4+ DCs. The unique functions of 
CD4+ DCs and double-negative DCs are not clearly understood, and will not be discussed 
further here.  
CD8α+ DCs were originally characterized based on the expression of MHCII+, 
CD11c+, and CD8α+. A newly described CD8α+ CX3CR1+ steady-state DC population in 
the spleen has made it necessary to use additional markers when defining the “classical” 
CD8α+ DCs. These markers include the C-type multilectin receptor DEC205 and the 
integrin CD103 (Bar-On et al., 2010). A unique function in antigen cross-presentation by 
CD8α+ DCs, described in detail below, was first proposed by den Haan and colleagues, 
and has since been the focus of intense study (den Haan et al., 2000). However, there are 
a number of challenges in studying CD8α+ DCs, such as their sparse numbers in the 
spleen, as well as challenges in extrapolating in vitro-generated data to the in vivo setting. 
DCs can be generated from bone marrow in vitro, either by culturing in GM-CSF 
and IL-4 (Inaba et al., 1992), or in Flt3 ligand (Flt3L) (Brasel et al., 2000), although each 
system has certain limitations. First, GM-CSF-derived DCs have characteristics of 
inflammatory DCs, and not steady-state populations (Xu et al., 2007). Conversely, Flt3L-
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derived DCs are more similar to in vivo steady-state populations, and can be divided into 
CD8α+ and CD4+ equivalent subsets (Naik et al., 2005). However, while these 
“equivalent” subsets resemble in vivo steady-state DCs in many respects, there are a 
number of discrepancies that make it difficult to reliably extrapolate in vitro-generated 
DC data to in vivo DC populations. For example, CD8α+ DC-equivalents from Flt3L 
cultures were originally described to be as efficient at cross-presentation as their in vivo-
generated counterparts (Naik et al., 2005). We had difficulty replicating this finding in 
our hands, and two recent papers have demonstrated that a maturation step is actually 
required to endow in vitro-generated DCs with cross-presentation ability (de Brito et al., 
2011; Sathe et al., 2011). Thus, it is unclear if in vitro-generated DCs can serve as an 
accurate model for in vivo populations. 
 
Batf3-/- mice as a tool to study CD8α+ DCs 
Due to the crucial function of DCs in the immune system, a number of tools have 
been generated to study these cells, such as mice genetically deficient in specific 
transcription factors involved in DC development. However, in vivo studies of DC 
subsets have also been limited up to this point, as all knockouts generated thus far exhibit 
multiple defects in a number of cells types, confounding any in vivo findings. For 
example, the transcription factor Irf8 is crucial in the development of CD8α+ DCs 
(Aliberti et al., 2003; Schiavoni et al., 2002), making it an attractive tool to study this 
subset. Yet the Irf8-deficient mice also lack plasmacytoid DCs (Tsujimura et al., 2003), 
and have reduced numbers of Langerhans cells (Schiavoni et al., 2004). Due to this 
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complexity, there are many gaps in our knowledge of DC function in vivo.  
BATF3 is an AP-1 family member transcription factor, expressed almost 
exclusively in conventional DCs. The Batf3-knockout mouse, generated in our lab by Kai 
Hildner, is specifically deficient in the lymphoid-resident CD8α+ DCs, and the related 
peripheral CD103+ DCs, without other abnormalities (Hildner et al., 2008; Edelson et al., 
2010). Thus, this mouse is an ideal tool to study the function of CD8α+ DCs in in vivo 
immune responses where cross-presentation is thought to be important. For example, 
CD8+ T cell priming to tumors requires DC cross-presentation of tumor antigens (Huang 
et al., 1994). Accordingly, Batf3-deficient mice fail to reject a fibrosarcoma cell line that 
is rapidly rejected by wild-type animals, highlighting the crucial role of CD8α+ DCs in 
priming CD8+ T cell responses to tumor antigen (Hildner et al., 2008). Cross-presentation 
is also important for initiation of CD8+ T cell responses to intracellular pathogens, as 
demonstrated by a failure of Batf3-/- mice to prime CD8+ T cell responses against West 
Nile and Sendai viruses in vivo (Hildner et al., 2008; Edelson et al., 2010). Thus, we 
investigated the response of Batf3-/- mice to another intracellular pathogen, Toxoplasma 
gondii. 
 
The Apicomplexan Toxoplasma Gondii 
The protozoan Toxoplasma gondii is a unicellular, obligate intracellular parasite 
that is the cause of the human and animal disease toxoplasmosis (Laliberte and 
Carruthers, 2008). The definitive host of T. gondii is the cat, wherein the parasite can 
undergo sexual reproduction. All other mammals can carry T. gondii and serve as 
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intermediate hosts. In humans, T. gondii infection is usually asymptomatic and self-
limiting, with the actively dividing form of T. gondii, the tachyzoites, being cleared by 
the immune system. Tachyzoites will convert to bradyzoites, or the latent form of T. 
gondii, under pressure from the immune response. Bradyzoites form tissue cysts within 
the brain and striated muscles, including the heart, where they set up a chronic infection 
(Laliberte and Carruthers, 2008). These tissue cysts are not eradicated by the immune 
system or medications, but do not cause disease in healthy individuals because they are 
maintained in a latent state (Laliberte and Carruthers, 2008). However, individuals with 
congenital or acquired immunodeficiencies (AIDS, immunosuppression after organ 
transplantation, etc.), can experience reactivation of the parasite with conversion of 
bradyzoites to tachyzoites and active replication (Hunter et al., 1994). The most serious 
consequences of infection in immunocompromised individuals include toxoplasmic 
encephalitis, toxoplasmic myocarditis, disseminated toxoplasmosis and death. Perinatal 
infection with T. gondii is also a serious and potentially fatal problem, and can lead to 
significant birth defects ranging from severe mental retardation to ocular disease (Yap et 
al., 2006).  
It is approximated that 25% of the world’s population has the chronic (latent) 
form of T. gondii, and toxoplasmosis is the third leading cause of death due to food-born 
illness in the US (Laliberte and Carruthers, 2008; CDC, 2008). Thus, as a significant 
human pathogen, there is great interest in understanding T. gondii pathogenesis. In 
addition, there is much to be learned from the interaction between the parasite and the 
host immune system. 
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The Mouse Immune Response to Toxoplasma Gondii 
The life cycle of T. gondii is very similar in humans and mice, and development 
of distinct acute and chronic phases of infection occurs in both species. In addition, 
similar immune effector functions are important for control of infection in both humans 
and mice, making analysis of these mechanisms in the mouse instrumental to 
understanding human immune responses. Cell-mediated immunity is critical for defense 
against T. gondii, although the precise cells responsible for initiating the protective 
responses have been difficult to identify. However, it has been clearly demonstrated that 
several immune effector mechanisms are vital in defense against T. gondii infection, 
including production of IL-12 and IFNγ, recruitment of inflammatory monocytes, and 
activation of T. gondii-specific CD8+ T cells. 
First, the effector cytokines IL-12 and IFNγ have been extensively studied in 
immune responses to T. gondii. Mice deficient in either cytokine rapidly succumb to 
infection by an avirulent strain of the parasite, dying within 9-13 days post infection, 
while 100% of wild-type animals survive at this dose (data not shown) (Scharton-Kersten 
et al., 1997a). A number of other cytokines such as TNFα and IL-1β have also been 
examined, but most have had a limited role in acute responses to this pathogen.  
During T. gondii immune responses, IL-12 is thought to function exclusively by 
eliciting production of IFNγ from other cell types, such as NK cells and T cells 
(Scharton-Kersten et al., 1996). The cellular source of IL-12 has been greatly investigated 
and debated, as this cytokine is necessary for the initiation of IFNγ-dependent responses, 
and will be discussed in detail below. IFNγ, on the other hand, activates various cell-
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intrinsic anti-parasitic defense pathways within infected cells (for review see (Yap et al., 
2006)).  
The major protective effects of IFNγ in mice are mediated through a group of 
genes collectively termed IRGs, or Immunity-Related GTPases (Taylor et al., 2000; Yap 
et al., 2006; Hunn et al., 2010). The expression of these genes is rapidly induced by IFNγ 
in all cell types, and the GTPases function by accumulating on the T. gondii 
parasitophorous vacuole (PV), which normally sequesters and protects the parasite within 
the host cell cytoplasm. The PV becomes ruffled and disrupted by the action of the IRGs, 
and the parasite is released into the cytoplasm, where it becomes moribund for unknown 
reasons (Zhao et al., 2009). Outside of the IRG family of proteins, IFNγ also induces NO 
production in certain cell types, which may function by limiting parasite respiration and 
replication (Scharton-Kersten et al., 1997b). Finally, the enzyme IDO is induced by IFNγ 
and depletes cellular tryptophan, which is an essential amino acid. Tryptophan starvation 
of T. gondii by IDO can also limit parasite replication and survival (Pfefferkorn, 1984; 
Fujigaki et al., 2002; Nagineni et al., 1996). 
In addition to a crucial role for effector cytokines in T. gondii immune responses, 
inflammatory monocytes have also been shown to be necessary for defense against this 
parasite after oral infection (Dunay et al., 2008). Gr1+F4/80+CCR2+ inflammatory 
monocytes are recruited to the site of infection by the chemokine CCL2. Mice deficient 
in either Ccr2 or Ccl2 succumb to oral infection with T. gondii due to a failure of 
inflammatory monocytes to home to the intestinal mucosa. The mechanism by which 
these monocytes protect the mouse against T. gondii is not known. Surprisingly, these 
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mice display normal serum levels of IFNγ and IL-12, suggesting a parallel but distinct 
requirement for inflammatory monocytes and effector cytokines (Dunay et al., 2008).  
Finally, T cell mediated adaptive immune responses to T. gondii are necessary for 
clearance of the pathogen. SCID mice, in which both CD4+ and CD8+ T cells are absent, 
fail to control T. gondii infection and die after 2 weeks (Scharton-Kersten et al., 1996). 
The same results are observed in Rag knockout animals, which lack both B and T cells. 
In addition, the loss of CD8+ T cells alone leads to comparable susceptibility, suggesting 
a crucial role for this cell type in the adaptive immune response to T. gondii (Goldszmid 
et al., 2007). Furthermore, Goldszmid et al. have demonstrated a requirement for the 
cross-presentation machinery for delivery of T. gondii antigens from within the parasite’s 
parasitophorous vacuole into the cytoplasm, where it can enter the MHCI pathway, 
allowing for recognition of infected cells by CD8+ T cells (Goldszmid et al., 2009). 
 
Interleukin-12 
 Interleukin-12 (IL-12) is a pro-inflammatory cytokine that was first described as a 
potent NK-stimulating factor (Kobayashi et al., 1989; Chan et al., 1991). IL-12 has been 
extensively characterized for its ability to stimulate IFNγ production, and to skew T cell 
differentiation to the T helper 1 (Th1) pathway (Hsieh et al., 1993; Trinchieri, 2003). In 
addition, IL-12 regulates CD8+ T cell expansion and contraction during infection 
(Takemoto et al., 2006; Curtsinger and Mescher, 2010). A number of cells are capable of 
producing IL-12 in different settings, including neutrophils, macrophages, and dendritic 
cells, as discussed below. IL-12-induced IFNγ mediates many of the pro-inflammatory 
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functions of  IL-12, including the activation of anti-microbial functions in innate immune 
cells such as macrophages (Trinchieri, 2003). Thus, IL-12 is a critical cytokine that 
functions as both a potent stimulator of innate immune defense mechanisms, as well as a 
bridge between the innate and adaptive immune systems that is crucial in regulating T 
cell responses. 
 IL-12 is a heterodimeric protein composed of two chains, p40 and p35. IL-12p35 
is expressed at low levels ubiquitously, while IL-12p40 expression is induced after 
cellular activation. The p40 chain is shared between IL-12 and IL-23, while the p35 chain 
is exclusive to IL-12. IL-12 is produced in response to toll-like receptor (TLR) 
engagement by microbial products (Ma and Trinchieri, 2001), and its production can also 
be enhanced by IFNγ, forming a positive-feedback loop in inflammatory settings (Ma et 
al., 1996). The IL-12 receptor (IL-12R) is composed of two chains, IL-12Rβ1 and IL-
12Rβ2, and receptor engagement leads to activation of signal transducer and activator of 
transcription 4 (STAT4), and transcription of target genes. IL-12R is mainly expressed on 
naïve and activated NK cells, and activated Th1 cells (Trinchieri, 2003). Furthermore, IL-
12R expression has been detected on dendritic cells, and IL-12 treatment of DCs in vitro 
has been shown to promote activation of the transcription factor NF-κB and prime DCs 
for both IL-12 production (Grohmann et al., 1998), and IFNγ production (Ohteki et al., 
1999), suggesting additional positive-feedback loops. However, the significance of these 
results has not been determined in physiologic settings in vivo. 
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Potential sources of IL-12 in response to T. gondii infection 
As mentioned above, the production of IFNγ in T. gondii infection is dependent 
on IL-12 (Gazzinelli et al., 1993). While a number of studies have identified cells capable 
of producing IL-12 in response to T. gondii, no study to date has unambiguously 
identified the cellular source of IL-12 in T. gondii infection relevant to protection in vivo. 
Several different cells have been proposed to be important sources of IL-12 during T. 
gondii infection, including neutrophils (Bliss et al., 1999; Bliss et al., 2000), macrophages 
(Gazzinelli et al., 1994; Robben et al., 2004), plasmacytoid dendritic cells (pDC) (Pepper 
et al., 2008), conventional dendritic cells (Liu et al., 2006), and the subset of conventional 
dendritic cells expressing CD8α (Reis e Sousa et al., 1997).  
Neutrophils have been reported to produce IL-12 in vitro in response to T. gondii 
antigens, but it is unlikely that they are required for protective immunity to T. gondi in 
vivo.  Neutrophils are rapidly recruited to the peritoneum after intraperitoneal infection 
with high doses of virulent strains of T. gondii, where they co-stain for IL-12 by 
microscopy (Bliss et al., 1999; Bliss et al., 2000). However, influx of neutrophils is not 
observed following oral infection with low virulence isolates, mimicking natural routes of 
infection (Dunay et al., 2008). Initial in vivo studies in which neutrophils were depleted 
using the Ly6C-specific antibody RB6-8C5 suggested a crucial function for neutrophils 
in protective immunity against T. gondii (Sayles and Johnson, 1996; Bliss et al., 2001; 
Scharton-Kersten et al., 1997b). However, inflammatory monocytes expressing the same 
marker Ly6C were later identified (Mordue and Sibley, 2003; Serbina and Pamer, 2006), 
and all studies conducted with RB6-8C5 were confounded by dual elimination of both 
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neutrophils and inflammatory monocytes. In a more recent study, Dunay et al. depleted 
only neutrophils in vivo using the Ly6G specific monoclonal antibody 1A8, and 
demonstrated that specific ablation of neutrophils does not increase the susceptibility of 
mice to T. gondii infection or alter serum levels of IL-12 (Dunay et al., 2010). These 
recent data would argue that neutrophils are less likely to be a critical in vivo source of 
IL-12 that is relevant to protection during T. gondii infection.  
Several cells other than neutrophils are viable candidates as an important source 
of IL-12 in providing protective immunity to T. gondii, including monocytes and 
macrophages. Gazzinelli et al. first demonstrated that thioglycolate elicited peritoneal 
macrophages produce IL-12 in response to in vitro stimulation with soluble tachyzoite 
antigen (STAg) (Gazzinelli et al., 1994). In addition, IL-12 mRNA could be detected in 
peritoneal exudate cells (PEC) of mice infected with T. gondii, although individual cell 
types from the PEC were not distinguished in this study. Robben et al. further 
demonstrated that low density (LOD) splenocytes as well as bone marrow-derived 
macrophages (BMM) were also capable of producing IL-12 in response to in vitro T. 
gondii infection (Robben et al., 2004). These studies demonstrate that activated or in vitro 
derived macrophages can produce IL-12, but do not demonstrate an in vivo function for 
these cells. In a model of oral infection, Dunay et al. demonstrate that Gr1+ inflammatory 
monocytes that are recruited to the intestine express IL-12 in vivo (Dunay et al., 2008), 
although a functional requirement for IL-12 production by these cells was not 
demonstrated. Plasmacytoid DCs can also produce IL-12 in response to in vitro infection 
by T. gondii (Pepper et al., 2008), although in this study, only in vitro generated bone-
12
marrow derived pDCs were examined, and an in vivo requirement for pDCs during T. 
gondii infection was not tested. Thus, while various monocyte, macrophage, and 
plasmacytoid DC populations can produce IL-12 in response to T. gondii, their 
importance as a source of IL-12 for in vivo protection against T. gondii infection has not 
been demonstrated and remains uncertain.   
Several studies have suggested that conventional DCs are important as a source of 
IL-12 in T. gondii infection, but these studies do not exclude macrophages or identify the 
type of DC that might be responsible for protection. One study used a lineage ablation 
approach in which the Diphtheria toxin (DT) receptor was expressed under control of the 
CD11c gene promoter to ask whether  dendritic cells were involved in protection against 
infection by T. gondii (Liu et al., 2006). DT administration in these mice caused the 
depletion of all CD11c-expressing cells and greatly increased susceptibility to T. gondii 
infection. Enhanced susceptibility was attributed to the depletion of IL-12-producing 
DCs, but could also result from loss of macrophages, since CD11c-DTR also depletes 
several subsets of splenic macrophages (Probst et al., 2005). Although transfer of wild-
type DCs, but not IL-12-deficient DCs, did rescue susceptibility in DT-treated mice, this 
rescue does not exclude macrophages as the cell that normally provides protection againt 
T. gondii infection in vivo. A recent study used CD11c-Cre and LysM-Cre in an attempt 
to selectively delete the TLR-adaptor protein MyD88 from DCs and macrophages, 
respectively (Hou et al., 2011).  Deletion of myd88 by CD11c-Cre was sufficient to 
decrease early IL-12 production during T. gondii infection and led to increased 
susceptibility, suggesting that IL-12 production by a CD11c-expressing cell was critical 
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for resistance to T. gondii infection. However, as with the study by Liu et al. above, 
CD11c is expressed by certain macrophage populations, making it difficult to discern 
unambiguously which cell is protective in vivo.  
A few studies have addressed the potential function of the CD8α+ DC subset in 
resistance to T. gondii. Studies of IRF8-deficient mice have suggested a role for the 
CD8α+ DC subset as a protective source of IL-12 in T. gondii infection (Scharton-
Kersten et al., 1997a), but such studies are inconclusive because these mice harbor 
additional defects beyond the loss of CD8α+ DCs. IRF8-deficient mice lack development 
of both CD8α+ DCs as well as pDCs (Aliberti et al., 2003; Tsujimura et al., 2003), and 
additionally have defects in activation of IFNγ-inducible genes (Tamura and Ozato, 
2002). Thus, the increased susceptibility of IRF8-/- mice to T. gondii infection (Scharton-
Kersten et al., 1997a) could result from the absence of either CD8α+ DCs or pDCs, or 
from a failure of IFNγ-induced effector mechanisms. Consistent with the latter, 
administration of IL-12 to IRF8-/- mice produces only a partial and temporary reduction 
in susceptibility to T. gondii (Scharton-Kersten et al., 1997a). In addition, CD8α+ DCs 
are the major source of IL-12 after intravenous administration of STAg (Reis e Sousa et 
al., 1997), although the relevance of this IL-12 to protection against live T. gondii has not 
been shown. In summary, although several cell types have been shown to be capable of 
producing IL-12 in response to T. gondii, the important cell type required for in vivo 
production of IL-12 after T. gondii infection has not been established. 
 
 
14
Summary of reported findings 
In this study, we used Batf3-/- mice (Hildner et al., 2008) that are specifically 
defective in the generation of the CD8α+ dendritic cell subset to address the function of 
these cells during T. gondii infection. Batf3-/- mice exhibit defective priming of T. gondii-
specific CD8+ T cells, decreased IL-12 and IFNγ production, and a dramatically increased 
susceptibility to T. gondii. Furthermore, this susceptibility in Batf3-deficient mice is 
reversed by administration of IL-12. Finally, we show that the CD8α+ dendritic cells are 
the only cells within the innate immune system whose IL-12 production is required for 
resistance to acute T. gondii infection.  
We also describe a novel function of IL-12 in regulating CD8α+ DC development. 
Administration of IL-12 can rescue the development of CD8α+ DCs in Batf3-/- mice in an 
IFNγ-dependent manner. In addition, IL-12 produced endogenously during the course of 
T. gondii infection can also restore CD8α+ DCs in Batf3-/- mice. Restored CD8α+ DCs in 
Batf3-/- mice are capable of producing IL-12 in vivo during T. gondii infection, and are 
similar in global gene expression to their wild-type counterparts. Finally, IL-12 treatment 
of Batf3-/- mice restores in vivo cross-presentation to necrotic cell-associated antigens, as 
well as CD8+ T cell priming to T. gondii-derived antigens, suggesting that restored 
CD8α+ DCs are capable of cross-presentation and priming.  
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CHAPTER 2 
Experimental Procedures 
 
Mice. Wild-type 129S6/SvEv, BALB/c, C57BL/6, and B6.SJL mice were 
originally purchased from Taconic and then bred in-house for experimental use. C57BL/6 
Rag2-/- mice were purchased from Taconic. IL-12p35-/- mice were purchased from 
Jackson Labs on both C57BL/6 and BALB/c backgrounds. Additional experimental 
C57BL/6 and B6.SJL mice were also purchased from Jackson Labs. Some experiments 
on the BALB/c background were done using C.Cg-Foxp3tm2Tch/J purchased from Jackson 
Labs that express an IRES-EGFP downstream of the Foxp3 gene; these mice were used 
as wild-type controls. Batf3-/- mice were previously generated in our laboratory (Hildner 
et al., 2008) on a 129S6/SvEv background, and subsequently backcrossed for 10 
generations onto both C57BL/6 and BALB/c backgrounds. The following mouse was 
obtained through the NIAID Exchange Program, NIH: C57BL6-Tg(OT-I)-RAG1tm1Mom 
004175 (Mombaerts et al., 1992; Hogquist et al., 1994). Kb-/- x Db-/- x β2-m-/- mice 
(C57/BL6 background) were a gift from Herbert W. Virgin and Ted Hansen, Washington 
University, St. Louis (Lybarger et al., 2003). 
Mice were age and sex-matched for each experiment, and were generally between 
8-15 weeks old. All mice were maintained under specific-pathogen-free conditions 
according to institutional guidelines and with protocols approved by the Animal Studies 
Committee of Washington University. 
 
16
Parasites and infections. The type II Prugniaud strain of T. gondii expressing a firefly 
luciferase and GFP transgene (PRU-FLuc-GFP) (provided by J. Boothroyd, Stanford 
University, Palo Alto, CA) was used in all tachyzoite experiments. The parasites were 
grown in culture in human foreskin fibroblasts as previously described (Robben et al., 
2004). For infections, freshly egressed parasites were filtered, counted, and injected 
intraperitoneally into mice. C57BL/6, 129S6/SvEv, and BALB/c mice were infected with 
100, 200, and 1,000 tachyzoites, respectively, for most experiments. BALB/c mice used 
for tetramer studies were infected with 5,000 tachyzoites. BALB/c bone marrow 
chimeras and controls were infected with 100 tachyzoites. 
For oral infection of mice, both the PRU-FLuc-GFP strain and the type II ME49 
strain of T. gondii expressing a firefly luciferase transgene (ME49-FLuc) (provided by 
Laura Knoll, University of Wisconsin, Madison, WI) were used. Outbred CD1 mice 
(Charles River Laboratories, Wilmington, MA) were infected ip with either 1,000 
tachyzoites or 5-10 tissue cysts, and used as the source of tissue cysts for experiments 1-3 
months after inoculation. To harvest cysts, animals were sacrificed, and the brains were 
removed and homogenized in 1mL of phosphate buffered saline (PBS). After counting, 5 
ME49-FLuc cysts or 20 PRU-FLuc-GFP cysts were administered to experimental 
animals via oral gavage. 
 
Luciferase imaging. Imaging was done as previously described (Saeij et al., 2005). 
Briefly, mice were given intraperitoneal injections of D-Luciferin (Biosynth AG, 
Switzerland) at 150mg/kg and allowed to remain active for 5 minutes. Animals were then 
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anesthetized with 2% isoflurane for 5 minutes, and then imaged using a Xenogen IVIS 
200 machine (Caliper Life Sciences). Data was analyzed using the Living Image software 
(Caliper Life Sciences).  
 
Histology. Mice were sacrificed on day 9 after infection, the spleen and ileum were 
harvested and fixed in 10% neutral buffered formalin. Tissues were dehydrates in 
ethanol, embedded in paraffin, and 5µm sections were stained with hematoxylin and 
eosin (H&E). 
 
In vitro T cell re-stimulation. 4 X 106 splenocytes from day 8 infected mice were 
incubated overnight in 100µL cIMDM with 100µg/mL GRA4 peptide (SPMNGGYYM). 
Brefeldin A at 1 µg/mL was added during the last 4 hours of incubation. Cells were then 
harvested and analyzed for IFNγ production using the intracellular cytokine staining 
protocol described above. 
 
T cell transfer into Rag-/- mice. Wild-type T cells were purified using Miltenyi Thy1.2 
microbeads and an LS cell separation column according to the manufacturer’s protocol. 
10 X 106 T cells were adoptively transferred into recipient animals one day prior to 
infection. 
 
ELISA/CBA. IL-12p40 levels were measured from serum samples using the Mouse IL-
12p40 OptEIA ELISA set (BD Bioscience). IFNγ serum levels were measured using the 
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BD CBA Mouse Inflammation Kit (BD Biosciences).  
 
Cell preparation. For all experiments except tetramer analysis, spleens were digested in 
5mL Iscove’s Modified Dulbecco’s Media (IMDM, Invitrogen) containing 10% fetal calf 
serum (HyClone) with 250µg/mL collagenase B (Roche) and 30 U/mL DNase I (Sigma-
Aldrich) for 1 hour at 37 degrees with agitation using stir-bars. For experiments 
analyzing intracellular cytokines, brefeldin A was added at 1 µg/mL during collagenase B 
and DNase I treatment, after which the cells were incubated for an additional 3 hours in 
IMDM with brefeldin A. Red blood cells were lysed by incubation in ACK lysis buffer. 
Cells were filtered through 80-µm strainers and counted on an analyzer (Vi-CELL, 
Beckman Coulter). 1-5 X 106 cells were stained for flow cytometric analysis. 
For T cell analysis using tetramers, spleens were disrupted in 2mL ACK lysis 
buffer, filtered through 80-µm strainers and counted on a Vi-CELL analyzer. 1-3 X 106 
cells were stained for flow cytometric analysis. 
For analysis of peritoneal cells, a peritoneal lavage was performed with 10mL 
Dulbecco’s PBS (DPBS). Harvested cells were incubated in ACK buffer to lyse red blood 
cells, filtered, counted, and stained for flow cytometry. 
 
Flow cytometry. Cells were incubated for 5 minutes at 4 degrees with Fc Block (clone 
2.4G2, BD) in FACS buffer (DPBS + 0.5% BSA + 2mM EDTA). Dead cells were 
excluded using LIVE/DEAD Aqua Fixable Dead Cell Stain Kit (Invitrogen). Surface 
staining was done for 20 minutes at 4 degrees in FACS buffer. For tetramer staining, cells 
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were incubated in the presence of tetramer and surface antibodies for 45 minutes at 4 
degrees. Absolute cell numbers were calculated using the total cell count multiplied 
successively by the percentages for the appropriate gates obtained through flow 
cytometry. Cells were analyzed on a BD FACSCantoII flow cytometer and data analyzed 
using FlowJo software (Tree star, Inc.). 
 
Intracellular Cytokine Staining. For intracellular cytokine staining, cells were first 
surface stained, then fixed in 2% paraformaldehyde for 15 minutes at room temperature. 
Cells were then re-suspended in permeabilization buffer (DPBS + 0.1% BSA + 0.5% 
saponin) and stained with anti-IL-12p40 or anti-IFNγ for 30 minutes at 4 degrees. 
 
Administration of IL-12. Recombinant murine IL-12 (Peprotech) was resuspended in 
pyrogen-free saline at a concentration of 2.5µg/mL, aliquoted and frozen at -80 degrees. 
For all T. gondii experiments, mice were injected ip with 0.5µg of IL-12 on days 0, 1, 2, 
3, and 4 after infection. For all other experiments, mice were injected ip with 0.5µg of IL-
12 either 3 times (days 0, 1, 2) or 1 time only (day 0), as specified in figure legends. 
 
In vitro NK cell culture. Splenocytes were incubated in 10ng/mL IL-12 and 50ng/mL 
IL-18 for 4 hours, with 1µg/mL brefeldin A added in for the last 3 hours. NK cells were 
identified using DX5 antibody, and stained for intracellular IFNγ. 
 
BM Chimera generation. This experiment was performed once on mice on the C57BL/6 
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background, and once on mice on the BALB/c background. Bone marrow from femurs 
and tibias were harvested, red blood cells lysed in ACK lysis buffer, filtered through 80-
µm strainers, and counted using the Vi-CELL analyzer (Vi-CELL, Beckman Coulter). 
Recipient mice were irradiated with 800 (BALB/c) or 1,200 (C57BL/6) rads of whole 
body irradiation. In the experiment using C57BL/6 mice, all recipients were WT 
C57BL/6 or B6.SJL. In the experiment using BALB/c mice, WT recipients were used for 
the WT donor BM condition, while Batf3-/- recipients were used for the Batf-/-, WT + 
Batf3-/-, and IL-12p35-/- + Batf3-/- donor BM conditions. The following day after 
irradiation, the recipients were injected intravenously with 2-4 million bone marrow cells 
from either a single donor or a 1:1 mixture from two donors. Mice were allowed to re-
constitute for 10 (C57BL/6) to 18 (BALB/c) weeks after transfer, and subsequently bled 
to determine chimerism. In experiments using C57BL/6 mice, the congenic markers 
CD45.1 and CD45.2 were used to determine percent chimerism using flow cytometry. In 
experiments using BALB/c mice, male/female donors were mixed to allow for analysis of 
chimerism using the Y-chromosome. Peripheral blood from chimeras was lysed for 
genomic DNA and analyzed by quantitative real time PCR for the presence of the gene 
Zfy1 on the Y chromosome using the following primers: Zfy1 (encoding zinc finger 
protein 1) Zfy1-forward, 5’-GCGTATCCTCATAAATGTGAC-3’, and Zfy1-reverse, 5’-
CATCTCTTACACTTGAATGG-3’. Rag2 (encoding recombination activation gene 2) 
was used as a normalization control, Rag2-forward, 5’- 
GGGAGGACACTCACTTGCCAGTA-3’, and Rag2-reverse, 5’- 
AGTCAGGAGTCTCCATCTCACTGA-3’. 
21
In vivo blockade of IFNγ . IFNγ-blocking antibody H22, and control antibody PIP were 
kindly provided by Robert Schreiber. For experiments performed with administration of 
IL-12, 250µg of PIP or H22 were administered ip on days -2 and +1, and 0.5µg of IL-12 
was administered ip in a single dose on day 0. Mice were harvested for analysis on day 3. 
 For experiments performed with T. gondii infection, 250µg of PIP or H22 were 
administered ip on days -1 and +2. Mice were infected on day 0, and harvested on day 7 
for analysis. 
 
In vivo depletion of NK cells. Anti-NK1.1 depleting antibody PK136, and control 
antibody MAR were kindly provided by Wayne Yokoyama. To deplete NK cells, 200µg 
of MAR or PK136 were administered ip on day -3, followed by 100µg or MAR or PK136 
as a second dose on day 0. Mice were also given 0.5µg of IL-12 on day 0, and harvested 
for analysis on day 3. Depletion of NK cells on the day of harvest was confirmed using 
DX5 and NKp46 antibodies. 
 
Microarray. For gene expression analysis CD8α+ DCs were isolated to greater than 99% 
purity from spleens using a FACSAria II (BD). CD8α+ DCs were identified as MHCII+ 
CD11c+ B220- CD24+ SIRPα- CD8α+ DEC205+ cells. Total RNA was prepared with the 
RNAqueous-Micro Kit (Ambion). RNA was labeled using the 3’ IVT Express Kit 
(Affymetrix), and the GeneChip Mouse Genome 430 2.0 Array (Affymetrix) was used as 
the platform. Expression data was analyzed using ArrayStar Software (DNASTAR).  
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In vivo cross-presentation assay. The in vivo cross-presentation assay was previously 
described in detail (den Haan et al., 2000). Briefly, OT-I-Tg CD8+ T cells were purified 
from OT-I-Tg Rag1-/- CD45.1 mice by positive selection using CD90.2 beads according 
to the manufacturer’s protocol. The purity of the T cell population was >99%. T cells 
were labeled with CFSE (Sigma-Aldrich) by incubation with 1 µM CFSE for 9 min at RT 
at a density of 2 X 107/mL. Subsequently cells were incubated with an equal volume of 
FCS and washed 2X with media containing 10% FCS. Cells were washed 2X with PBS, 
and 2 X 105- 1 X 106 cells were injected ip into recipient mice.  
Splenocytes from Kb-/- x Db-/- x β2-m-/- mice (gift from Herbert W. Virgin and 
Ted Hansen) were prepared in serum-free medium, and loaded with 10mg/mL ovalbumin 
(Calbiochem) by osmotic shock. 2.5 X 107 cells were incubated in 170µl of hypertonic 
medium (0.5M sucrose, 10% wt/vol polyethylene glycol 1000, and 10mM Hepes in 
RPMI 1640, pH 7.2) alone or in the presence of 10mg/mL ovalbumin for 10 minutes at 
37 degrees. 2.2 mL of pre-warmed hypotonic medium (40% H2O, 60% RPMI 1640) was 
added followed by an additional 2 minutes of incubation at 37 degrees. The cells were 
washed 2X with cold PBS, irradiated at 1,350 rads, and injected IV 3 days after OT-I 
transfer. Mice were harvested 3 days after administration of antigen, and CD45.1+ OT-I T 
cells analyzed for CFSE dilution. 
 
Quantitative RT-PCR. For gene expression analysis various cell types were isolated to 
greater than 99% purity from spleens using a FACSAria II (BD). Total RNA and cDNA 
were prepared with the RNeasy Micro Kit (Qiagen) and Superscript III reverse 
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transcriptase (Invitrogen). For real-time PCR, StepOnePlus Real-Time PCR System 
(Applied Biosystems) was used according to the manufacturer's instructions, using the 
Quantitation, Standard-Curve method and SYBR Green PCR master mix. PCR conditions 
were 10 min at 95 °C, followed by 40 two-step cycles consisting of 15 s at 95 °C and 1 
min at 60 °C.  
For analysis of TLR11 expression, dendritic cells and neutrophils were identified 
using the following antibodies: PDCA, CD11c, B220, CD4, CD8, GR1 and CD11b. 
Listed are only the markers for which they express: CD4 DC = CD11c+ CD4+, CD8 DC = 
CD11c+ CD8+, Plasmacytoid DC = CD11c+ B220+ PDCA+, Neutrophils = GR1+ CD11b+. 
Lymphoid cells were identified using the following antibodies: CD4, CD8, B220, CD11b 
and CD11c. Listed are only the markers for which they express: CD4 T cells = CD4+, 
CD8 T cells = CD8+, B cells = B220+. Monocytes were isolated from bone marrow and 
expressed CD11b and Ly-6C. 
For analysis of IL-23p19, IL-12p35 and IL-12/23p40 subunits, CD8α+ DCs were 
sorted based on the following markers: PDCA- MHCII+ CD11c+ CD8α+ DEC205+. As a 
control, total splenic CD11c+ cells were purified using Miltenyi microbeads to negatively 
select for cells expressing B220, Thy1.2, and DX5, followed by positive selection using 
CD11c (done according to the manufacturer’s protocol). In addition, RNA was harvested 
from whole kidney lysate as well as from the macrophage cell line J774 to serve as 
positive and negative controls. 
For analysis of Batf3, Batf, and IRF-8, CD8α+ DCs were sorted based on the 
following markers: B220- CD3- NKp46- MHCII+ CD11c+ CD8α+ DEC205+. For positive 
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and negative controls for Batf, RNA from WT or Batf-/- B cells stimulated with LPS for 1 
day was used. For positive and negative controls for IRF-8, RNA from in vitro cultured 
CD8α+ or CD4+ equivalent DCs was used. 
Primers used to evaluate relative expression were as follows: TLR11 (encoding 
toll-like receptor 11) TLR11-forward, 5'-TGATGTATTCGTGTCCCACTGC-3', and 
TLR11-reverse, 5'- CCACTCTTTCTCTCCTCTTCCTCG-3'. IL-23p19 (encoding 
interleukin 23, alpha subunit p19) IL-23p19-forward, 5’- 
AGCGGGACATATGAATCTACTAAGAGA-3’, and IL-23p19-reverse, 5’- 
GTCCTAGTAGGGAGGTGTGAAGTTG-3’ (Uhlig et al., 2006). IL-12p35 (encoding 
interleukin 12A) IL-12p35-forward, 5’- 
TACTAGAGAGACTTCTTCCACAACAAGAG-3’, and IL-12p35-reverse, 5’- 
TCTGGTACATCTTCAAGTCCTCATAGA-3’ (Uhlig et al., 2006). IL-12/23p40 
(encoding interleukin 12B) IL-12/23p40-forward, 5’- 
GACCATCACTGTCAAAGAGTTTCTAGAT-3’, and IL-12/23p40-reverse, 5’- 
AGGAAAGTCTTGTTTTTGAAATTTTTTAA-3’ (Uhlig et al., 2006). Batf3 (encoding 
basic leucine zipper transcription factor, ATF-like 3) Batf3-forward, 5’-
GCTCAGAGGAGCCGGAAGA-3’, and Batf3-reverse, 5’-
CTGCGCAGCACAGAGTTCTC-3’. Batf (encoding basic leucine zipper transcription 
factor, ATF-like) Batf-forward, 5’-CGACAGCAGTGACTCCAGCTT-3’, and Batf-
reverse, 5’-CTCTGAACTTTCCTCACATCATCAG-3’. Irf8 (encoding interferon 
regulator factor 8) IRF-8-forward, 5’-TGCCACTGGTGACCGGATAT-3’, and IRF-8-
reverse, 5’-GACCATCTGGGAGAAAGCTGAA-3’. Hprt1 (encoding hypoxanthine 
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guanine phosphoribosyl transferase) was used as a normalization control, HPRT-forward, 
5'-TCAGTCAACGGGGGACATAAA-3', and HPRT-reverse, 5'-
GGGGCTGTACTGCTTAACCAG-3'. 
 
Antibodies. The following antibodies were purchased from BD: PE-Cy7 anti-CD11b 
(M1/70); PE-Cy7 anti-CD4 (RM4-5); APC anti-CD3e (145-2C11); PerCP-Cy5.5 anti-
CD8a (53-6.7); V450 anti-CD8a (53-6.7); APC anti-CD8a (53-6.7); PE-Cy7 anti-CD8a 
(53-6.7); PE anti-Thy1.2 (30-H12); V450 anti-Ly-6C (AL-21); APC anti-IFNg 
(XMG1.2); PE-Cy7 anti-IFNg (XMG1.2); APC anti-IL-12p40/p70 (C15.6); Rat IgG1, 
κ APC (R3-34); V450 anti-Gr1 (RB6-8C5) 
The following antibodies were purchased from eBioscience: eFluor 450 anti-
MHCII I-A/I-E (M5/114.15.2); APC-eFluor 780 anti-CD11c (N418); APC-eFluor 780 
anti-CD4; PE-Cy7 anti-B220 (RA3-6B2); APC-eFluor 780 anti-B220 (RA3-6B2); PE 
anti-CD103 (2E7); eFluor 450 anti-CD317 (PDCA) (eBio927); eFluor 450 anti-CD335 
(NKp46) (29A1.4); 
The following antibodies were purchased from Miltenyi: PE anti-DEC205 
(NLDC-145); APC anti-DEC205 (NLDC-145); PE anti-Ly-6G (1A8) 
 
Statistics. For analyses of survival data the log-rank test was used. For analyses of all 
other data, an unpaired, two-tailed Student’s t test with a 95% confidence interval was 
used (Prism; GraphPad Software, Inc.). All data are represented as means +/- SD. 
26
CHAPTER 3 
Batf3-/- Mice are Highly Susceptible to T. gondii Infection 
 
We first compared the survival of wild-type and Batf3-/- mice to infection with 
T. gondii (Fig. 1). Intraperitoneal (ip) infection by tachyzoites of the type II avirulent 
Prugniaud (Pru) strain of T. gondii revealed a significantly increased susceptibility of 
Batf3-/- mice relative to wild-type mice (Fig. 1 A). While wild-type mice were resistant to 
T. gondii infection, infection of Batf3-/- mice was uniformly lethal in all genetic 
backgrounds tested and led to death within 9 to 10 days after infection. Using a T. gondii 
strain harboring a firefly luciferase transgene reporter, we observed approximately 100-
fold increased parasite burden within 5 days following infection in Batf3-deficient mice 
compared to wild-type mice (Fig. 1, B and C). This exponential parasite growth 
continued in the Batf3-/- mice throughout the course of infection.  
To extend our findings, we challenged wild-type and Batf3-/- mice with T. 
gondii cysts by oral gavage, which simulates the natural route of infection. Oral challenge 
of Batf3-/- mice demonstrated a similar susceptibility of these animals to T. gondii 
infection, with acute lethality and a failure to control parasite replication (Fig. 2, A and 
B). In addition, histological analysis of the spleen and ileum revealed extensive 
inflammation and destruction of tissue architecture in Batf3-/- mice 9 days after infection 
(Fig. 2 C).  
In summary, Batf3-/- mice are highly susceptible to T. gondii infection 
compared with wild-type mice using both the ip route of tachyzoite challenge (Fig. 1), as 
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well as the oral route of tissue cyst challenge (Fig. 2). However, the underlying 
mechanism following oral challenge is likely to be complex and distinct from the 
underlying mechanism following tachyzoite challenge, and will be the focus of future 
studies. Specifically, gut CD103+ DCs are also absent in the Batf3-/- mice (Edelson et al., 
2010), and may play a role during oral challenge where the parasite’s initial site of 
infection and replication is the small intestine. All other experiments in this work were 
performed following intraperitoneal tachyzoite challenge.  
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Figure 1. Batf3-/- mice rapidly succumb to infection with an avirulent strain of 
Toxoplasma gondii. Mice were infected with T. gondii tachyzoites ip, monitored for 
survival (A) and parasite burden (B and C). (A) Combined survival data from infected 
C56BL/6, 129S6/SvEV and BALB/c wild-type (solid line, n=30) and Batf3-/- (dashed 
line, n=29) mice from 8 independent experiments. (B) Infected wild-type (squares) and 
Batf3-/- (triangles) mice underwent whole body in vivo imaging throughout the course of 
infection to measure bioluminescence. Data shown is combined parasite burden from 
infected 129S6/SvEV mice from 2 independent experiments (n=5-8 at each time-point, 
representative of 6 independent experiments). Data are represented as mean +/- standard 
deviation. (C) Representative bioluminescence images of infected 129S6/SvEV mice 
throughout the course of infection. ***: P<0.001. 
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Figure 2. Batf3-/- mice are highly susceptible to oral infection with T. gondii cysts 
and cannot control parasite replication. Mice were infected with 5 ME49-FLuc tissue 
cysts by oral gavage, and monitored for survival (A) and parasite burden (B). (A) 
BALB/c wild-type (solid line) and Batf3-/- (dashed line) mice were monitored for survival 
over the course of the experiment (n=5, representative of 2 independent experiments). (B) 
Infected wild-type and Batf3-/- mice were monitored by whole body in vivo 
bioluminescence imaging on day 7 and 9 after infection (n=5, representative of 2 
independent experiments). Horizontal lines represent the geometric mean. (C) 
129S6/SvEV wild-type and Batf3-/- mice were infected with 20 PRU-FLuc-GFP tissue 
cysts and sacrificed on day 9 after infection for H&E analysis of the spleen and ileum. 
(C) was performed by Ildiko Dunay. *: 0.01<P<0.05, **: 0.001<P<0.01. 
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CHAPTER 4 
CD8α+ DCs are Required for CD8+ T Cell Priming to Endogenous T. gondii 
Antigens 
 
Priming of CD8+ T cells in the acute phase of infection is defective in Batf3-/- mice 
CD8+ T cells are required for effective control of T. gondii infection (Goldszmid 
et al., 2007), and priming of CD8+ T cell responses to T. gondii requires the unique 
mechanism of cross-presentation (Goldszmid et al., 2009). In order to determine if CD8+ 
T cell priming to this parasite is diminished in the absence of the main cross-presenting 
cells, the CD8α+ DCs, we utilized T. gondii specific tetramers (kindly provided by Dr. 
Hidde Ploegh). Tetramers are a chemically linked group of four MHCI molecules 
containing specific peptides that are recognized by CD8+ T cells. The tetramers are linked 
to a fluorescent dye, and used to detect T cells that express a T-cell receptor specifically 
recognizing the given peptide. We used two MHCI tetramers to measure the expansion of 
CD8+ T cells specific for peptides derived from the GRA4 and GRA6 dense granule 
proteins of T. gondii (Frickel et al., 2008). Tetramer positive CD8+ T cells were 
significantly increased 8 days after infection with T. gondii in the spleen of wild-type 
mice, but not in Batf3-/- mice (Fig. 3 D). Tetramer staining in the peritoneum suggested a 
similar trend, although the data did not reach significance due to substantial variability in 
the observed response in wild-type mice (Fig. 3 A-C). Total splenic CD8+ T cell numbers 
were comparable between wild-type and Batf3-/- mice both before and after infection 
(Fig. 4 B), consistent with a normal T cell compartment in Batf3-/- mice (Hildner et al., 
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2008). However, the total number of peritoneal CD8+ T cells appeared to be highest in 
infected wild-type mice (Fig. 4 A), suggesting local proliferation or recruitment of 
activated cells, although again this increase did not reach significance as compared to 
Batf3-/- numbers.  
In addition, using the GRA4 peptide to activate splenic antigen-specific CD8+ T 
cells harvested 8 days after infection, we observed a significant increase in peptide 
induced IFNγ production from wild-type CD8+ T cells, but not from Batf3-/- CD8+ T cells 
(Fig. 3 E). Thus, Batf3-/- mice have reduced priming of IFNγ-producing CD8+ T cells 
after infection by T. gondii, suggesting that CD8α+ DCs contribute to the priming of 
CD8+ T cells against this intracellular pathogen.  
Although priming of T. gondii-specific CD8+ T cells is reduced in infected Batf3-/- 
mice (Fig. 3), the rapid lethality of T. gondii infection in Batf3-/- mice suggests a defect in 
an innate rather than adaptive immune response. To further exclude a role for Batf3 in T 
cells in the acute lethality observed, we transferred wild-type purified T cells into Rag-
deficient mice that were either wild-type or deficient for Batf3. Rag-/- mice cannot 
generate T or B cells due to a failure to recombine and express the required receptors, and 
therefore the only T cells present in these mice will be the transferred wild-type cells. 
Batf3/Rag-double deficient animals that were given wild-type T cells are 
indistinguishable from Batf3-/- mice when examined for parasite burden after T. gondii 
infection (Fig. 5), suggesting that the defect observed in Batf3-/- mice is restricted to the 
innate compartment. Therefore, we next focused on identifying the innate function of 
CD8α+ DCs necessary for protection against T. gondii infection. 
32
Tetramer
C
D
8
Gra6
Gra4
Uninfected WT Batf3-/-
Peritoneal cells
0.000
0.001
0.002
0.003
0.004
0.005
G
ra
4+
 C
D
8 
T 
C
el
l #
 (X
10
6 )
0.000
0.001
0.002
0.003
G
ra
6+
 C
D
8 
T 
C
el
l #
 (X
 1
06
)
0.000
0.005
0.010
0.015
0.020 *
G
ra
4+
 C
D
8 
T 
C
el
l #
 (X
 1
06
)
%
 IF
N
g+
WT Batf3-/-
Infection: - -+ +
0.0
0.5
1.0
1.5 *
A
B C
D E
0.40% 0.09%0.02%
0.29% 0.02%0.01%
WT Batf3-/-
Infection: - -+ +
WT Batf3-/-
Infection: - -+ +
WT Batf3-/-
Infection: - -+ +
Peritoneal cells Peritoneal cells
Splenocytes CD8 T cells
ns ns
Figure 3. CD8+ T cell priming to T. gondii is defective in Batf3-deficient mice. 
BALB/c wild-type and Batf3-/- mice were infected with T. gondii, sacrificed on day 8 
after infection, and analyzed for CD8+ T cell priming by tetramer staining ex vivo (A-D) 
and intracellular cytokine staining following peptide re-stimulation in vitro (E). (A) 
Representative plots of Ld-GRA4 and Ld-GRA6 tetramer staining in the peritoneum, with 
percentage of total peritoneal cells that are tetramer positive shown. (B-D) Absolute 
numbers of CD8+ tetramer-positive cells in the peritoneum (B and C) or spleen (D) 
specific for GRA4 (B and D) or GRA6 (C) on day 8 after infection (n=3, representative 
of 2 independent experiments). (E) Absolute numbers of IFNγ-positive CD8+ T cells as 
measured by intracellular cytokine staining after overnight re-stimulation of whole 
splenocytes with the GRA4 peptide (n=5). (B-E) Data are represented as mean +/- 
standard deviation. Not significant (ns): P>0.05, *: 0.01<P<0.05. 
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Figure 4. CD8+ T cell compartment is normal in Batf3-/- mice. (A and B) BALB/c 
wild-type and Batf3-/- mice were infected with T. gondii, sacrificed on day 8 after 
infection, and analyzed for total numbers of CD8+ T cells in the spleen (B) and 
peritoneum (A) (n=3). Data are represented as mean +/- standard deviation. Not 
significant (ns): P>0.05. 
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Figure 5. The presence of wild-type T cells in Batf3-/- mice does not change their 
susceptibility to T. gondii infection. C57BL/6 wild-type, Batf3-/-, Rag-/-, or Batf3/Rag-/- 
mice were infected with T. gondii and parasite burden measured by in vivo 
bioluminescence imaging on day 7 or 8 after infection. In two groups, wild-type T cells 
were adoptively transferred into the recipient mice one day before infection. Horizontal 
lines represent the geometric mean. *: 0.01<P<0.05, **: 0.001<P<0.01, ***: P<0.001. 
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CHAPTER 5 
IL-12 Production by CD8α+ DCs is Required for Protection Against Acute T. gondii 
Infection 
 
IL-12 and IFNγ  production are defective in T. gondii-infected Batf3-/- mice. 
To determine if the crucial effector cytokines IL-12 and IFNγ were being 
produced normally in Batf3-/ mice, we next examined the serum levels of these cytokines. 
The IL-12 subunit p40, which is shared with the cytokine IL-23, is used as the readout for 
IL-12 in all cases, since IL-23 plays no role in acute T. gondii infection in the mouse 
(Lieberman et al., 2004). IL-12p40 levels in serum were markedly reduced in Batf3-/- 
mice relative to wild-type mice infected with T. gondii (Fig. 6 A). In wild-type mice, 
serum IL-12p40 began to increase on day 3 after infection, and increased until 7 days 
after infection. In contrast, IL-12p40 remained at basal levels in Batf3-/- mice until day 5 
after infection, at which point its increase was significantly reduced relative to wild-type 
mice for the remainder of infection. The decrease in IL-12p40 production in Batf3-/- mice 
correlated with significantly reduced levels of serum IFNγ (Fig. 6 B). In wild-type mice, 
IFNγ production began to increase after 4 to 5 days of infection, reaching a peak at day 8. 
By contrast, IFNγ showed no increase in Batf3-/- mice for 5 days after infection, and 
showed only a slight increase on day 7, when it was significantly reduced relative to 
wild-type mice.  
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CD8α+ DCs increase in early infection by T. gondii and are the major producers of IL-
12.  
 In uninfected wild-type mice, the CD8α+ subset of conventional dendritic cells 
comprises approximately 5-10% of the total DC compartment in the spleen, depending on 
the mouse strain (Hildner et al., 2008). CD8α+ DCs also express several surface markers 
such as CD103, CD24 and DEC205 that distinguish it from the newly described 
CX3CR1+ CD8α+ DC subset that is distinct from classical CD8α+ DCs (Bar-On et al., 
2010), and one of these additional markers is used in every experiment to ensure 
exclusion of the CX3CR1-expressing subset. The remainder of conventional DCs are 
distributed between those expressing high levels of CD11b, or low levels of CD11b. 
After infection by T. gondii, we observed that the percentage of CD8α+ DCs in wild-type 
mice increased to represent approximately 20% of the total dendritic cell compartment in 
the spleen by 7 days after infection (Fig. 7 A). By contrast, Batf3-/- mice lacked CD8α+ 
DCs as previously reported (Hildner et al., 2008) and showed no increase at any time 
after infection. Beyond this increase in their percentage, CD8α+ DCs also increased in 
absolute numbers in the spleens of wild-type mice after T. gondii infection (Fig. 7 B). By 
contrast, CD11b+ DCs were present in similar numbers during all times after T. gondii 
infection in both wild-type and Batf3-/- mice (Fig. 8, A and B).  
Increased numbers of CD8α+ DCs after T. gondii infection suggests a role in 
protection against this parasite. Therefore, production of IL-12p40 by various cell types 
was measured in wild-type and Batf3-/- mice after infection by T. gondii (Fig. 9 and 10). 
We examined day 3 after infection specifically, since we were interested in cells 
37
producing IL-12p40 early enough after infection that could control the exponential 
growth of T. gondii observed as early as day 4 in Batf3-/- mice (Fig. 1 B). We used 
intracellular cytokine staining (ICS) to quantify IL-12p40 production by CD8α+ DCs, 
CD11b+ DCs, plasmacytoid DCs, inflammatory monocytes and neutrophils. The 
percentage of CD8α+ DCs producing IL-12p40 was increased from basal levels in 
uninfected mice to approximately 25-30% at day 3 after infection (Fig. 9). By contrast, 
the percentage of CD11b+ DCs that produced IL-12p40 was not significantly altered by 
infection, being approximately 2 to 3% in both infected and uninfected mice (Fig. 9). 
Furthermore, inflammatory monocytes, neutrophils and plasmacytoid DCs displayed no 
induction of IL-12p40 by T. gondii infection (Fig. 10). Accordingly, CD8α+ DCs express 
the highest levels of the T. gondii profilin sensor TLR11 as compared with a variety of 
immune cell types (Fig. 11), suggesting that this cell is optimally poised for sensing T. 
gondii and producing initial IL-12 during early infection. In addition, since the IL-12p40 
chain is shared between the cytokines IL-12 and IL-23, we formally excluded a role for 
IL-23 in our system by examining CD8α+ DC induction of the IL-23-specific subunit p19 
and the IL-12-specific subunit p35 upon infection. Uninfected and infected CD8α+ DCs 
express the IL-12p40 subunit (Fig. 12 A), as shown above, in conjunction with the IL-
12p35 subunit (Fig. 12 B), but not the IL-23p19 subunit (Fig. 12 C), clearly showing 
production of IL-12 and not IL-23 by these cells. In addition, expression of IL-12p40 is 
significantly increased in these cells on day 3 after infection (Fig. 12 A). In summary, our 
data demonstrates that CD8α+ DCs are the major IL-12-producing cells in the spleen 3 
days after infection by T. gondii. 
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IL-12 administration to Batf3-/- mice restores IFNγ  production and controls T. gondii 
infection.  
If susceptibility of Batf3-/- mice to T. gondii results from decreased IL-12 
production caused by the absence of CD8α+ DCs, then administration of IL-12 to Batf3-/- 
mice should restore their resistance to infection. Administration of recombinant murine 
IL-12 to wild-type mice had no impact on their susceptibility to infection by T. gondii 
(Fig. 13 A). In contrast, administration of IL-12 to Batf3-/- mice during the first 5 days of 
infection dramatically reversed their susceptibility, promoting their survival after 
infection for more than 60 days. Moreover, IL-12 treatment of Batf3-/- mice reduced their 
pathogen burden compared to untreated Batf3-/- mice, bringing parasite loads to levels in 
wild-type mice (Fig. 13, B and C).  
Since reduced IL-12 in Batf3-/- mice may cause susceptibility to T. gondii by 
lowering early IFNγ production, and since NK cells are a significant source of IFNγ in 
response to IL-12, we asked if Batf3-/- NK cells could produce IFNγ in vitro. After culture 
with IL-12 and IL-18, wild-type and Batf3-/- NK cells produce equivalent amounts of 
IFNγ as measured by intracellular cytokine staining (Fig. 14). We next asked whether IL-
12 administration to Batf3-/- mice also restored normal IFNγ production during infection 
(Fig. 15 A-D). IL-12 administration to wild-type mice did not influence serum IFNγ 
levels at day 4 after infection (Fig. 15 A). However, IL-12 administration to Batf3-/- mice 
significantly increased serum IFNγ on day 4, which approximated levels found in 
infected wild-type mice. The IFNγ induced by IL-12 in Batf3-/- mice appeared to arise 
from several cell types (Fig. 15 B-D). NK, CD4+ and CD8+ T cells from infected wild-
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type mice produced IFNγ by ICS on day 3 when examined immediately ex vivo, but NK, 
CD4+ and CD8+ T cells from infected Batf3-/- mice were devoid of IFNγ at this time. 
However, administration of IL-12 to Batf3-/- mice infected with T. gondii substantially 
restored levels of IFNγ production by all three cell types. In summary, IL-12 
administration to Batf3-/- mice reverses their susceptibility to T. gondii infection, 
decreases pathogen burden, and increases IFNγ production by natural killer cells and T 
lymphocytes. 
 
CD8α+ DCs are the only cell whose IL-12 production is required to control acute T. 
gondii infection.  
 The fact that CD8α+ DCs are a major source of IL-12 during acute T. gondii 
infection does not prove that they are the only source of IL-12 capable of controlling 
infection, and their requirement for protection against acute infection may derive from 
different, unknown functions. To test whether IL-12 production by CD8α+ DCs is 
relevant for resistance to acute T. gondii infection, we generated mixed chimeras using 
bone marrow (BM) derived from IL-12p35-/- and Batf3-/- mice. CD8α+ DCs can develop 
from IL-12p35-/- BM, but not Batf3-/- BM. This protocol allows the generation of 
chimeras in which CD8α+ DCs now develop but are unable to produce IL-12, while all 
other immune cell types can produce IL-12. If CD8α+ DCs are solely required for 
providing an early source of IL-12, then the mixed chimeras will remain susceptible to 
infection. 
For this experiment, several other chimeras are necessary as controls. We 
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generated chimeras receiving only wild-type, Batf3-/-, or IL-12p35-/- BM, as well as mixed 
chimeras receiving wild-type BM with either Batf3-/- or IL-12p35-/- BM (Fig. 16 and 17). 
This experiment was performed once using BALB/c mice (Fig. 16) and once using 
C57BL/6 mice (Fig. 17); both experiments are shown as the data are complementary. 
Chimeras were in general more susceptible to death following infection as compared with 
non-chimeric controls, potentially due to long-term effects of lethal irradiation. To allow 
for analysis of survival kinetics following infection, the dose of T. gondii was reduced in 
the BALB/c experiment from 1,000 tachyzoites to 100 tachyzoites. This was not possible 
in the C57BL/6 experiment, since the LD50 in this strain is much lower than in BALB/c 
mice, and C57BL/6 mice are routinely infected with only 100 tachyzoites; reduction of 
the dose below 100 tachyzoites could not be performed reproducibly. On the other hand, 
the experiment performed on C57BL/6 mice was more complete overall, as two 
additional controls were added to measure the response in chimeras re-constituted with 
IL-12p35-/- BM alone, or with wild-type plus IL-12p35-/- BM. 
Chimeras of all 6 types were infected with T. gondii and analyzed along with non-
chimera controls for survival and parasite burden (Fig. 16 and 17). First, chimeras 
reconstituted with wild-type BM controlled parasite numbers as expected, with burden 
equivalent to wild-type non-chimeric mice. The majority of these mice also survived 
acute infection. Chimeras reconstituted either with Batf3-/- or IL-12p35-/- BM succumbed 
to acute infection as expected and showed high parasite burdens, each approximately 
100-fold higher that wild-type, reflecting the phenotype of the respective mutant non-
chimeric mice.  
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We next examined mixed bone marrow chimeras. Mixed chimeras reconstituted 
with wild-type plus Batf3-/- BM or IL-12p35-/- BM showed low parasite burdens, 
equivalent to wild-type mice and chimeras reconstituted with wild-type BM. In both of 
these mixed chimeras, only half of the cells would harbor a defect, and the other half 
would be normal. Thus, a half cell complement of normal cells appears sufficient for 
normal control of parasite burden. 
 Finally, we analyzed chimeras reconstituted with a mixture of Batf3-/- and IL-12-
p35-/- BM. In these chimeras, CD8α+ DCs develop only from IL-12p35-/- BM, whereas all 
other cells develop from both IL-12-sufficient and IL-12p35-/- BM. Thus, in these 
chimeras, the CD8α+ DCs uniformly lack the capacity to produce IL-12, whereas all 
other cell types retain the capacity to produce IL-12. These mixed chimeras are highly 
susceptible to infection and have extremely high parasite burden, comparable to levels in 
Batf3-/- mice. These results indicate that the CD8α+ DCs are the only cell whose IL-12 
production is sufficient for controlling parasite burden and maintaining resistance to 
acute T. gondii infection. 
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Figure 6. Batf3-/- mice have reduced serum IL-12 and IFNγ during Toxoplasma 
gondii infection. Infected 129S6/SvEV wild-type (squares) and Batf3-/- (triangles) mice 
were bled at various time-points after infection, and serum analyzed for cytokine levels. 
Data represents combined serum levels of IL-12p40 (A) and IFNγ (B) through the course 
of infection from 2-3 independent experiments (n=3-5 at each time-point). Data are 
represented as mean +/- standard deviation. *: 0.01<P<0.05, **: 0.001<P<0.01, ***: 
P<0.001. 
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Figure 7. Splenic CD8α+ dendritic cells expand after T. gondii infection in wild-type 
mice. 129S6/SvEV wild-type and Batf3-/- mice were infected with T. gondii, sacrificed on 
days 0, 3, 5 and 7 after infection, and analyzed for changes in dendritic cell subsets by 
flow cytometry. (A) Representative FACS plots gated on Aqua-negative, MHCII+, 
CD11c+ conventional dendritic cells. (B) Absolute numbers of CD8α+ CD103+ DCs in 
the spleen of wild-type (black bars) and Batf3-/- (white bars) mice throughout the course 
of infection (n=3, representative of 2 independent experiments). Data are represented as 
mean +/- standard deviation. 
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Figure 8. CD11b+ DC percentages or numbers do not change during T. gondii 
infection. 129S6/SVeV wild-type and Batf3-/- mice were infected with T. gondii 
tachyzoites ip, and harvested on days 0, 3, 5 and 7 after infection. (A) Representative 
FACS plots gated on MHCII+ CD11c+ cells. (B) Absolute numbers of CD11b+ DCs in the 
spleen of wild-type (black bars) and Batf3-/- (white bars) mice throughout the course of 
infection (n=3, representative of 2 independent experiments). Data are represented as 
mean +/- standard deviation. 
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Figure 9. CD8α+ dendritic cells are the major producers of IL-12 after T. gondii 
infection in wild-type mice. 129S6/SvEV wild-type and Batf3-/- mice were infected with 
T. gondii, sacrificed on day 3 after infection, and analyzed for the cellular source of IL-12 
by intracellular cytokine staining. Representative FACS plots gated on MHCII+ CD11c+ 
expressing CD11b+ DCs or CD8α+ DEC205+ DCs are shown. (n=3, representative of 3 
independent experiments). 
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Figure 10. Neutrophils, inflammatory monocytes and plasmacytoid DCs do not 
produce IL-12p40 upon T. gondii infection. 129S6/SvEV wild-type and Batf3-/- mice 
were infected with T. gondii, sacrificed on day 3 after infection, and analyzed for the 
cellular source of IL-12 by intracellular cytokine staining. Representative FACS plots 
gated on Ly-6G+ CD11b+ neutrophils, Ly-6G- Ly-6C+ CD11b+ inflammatory monocytes, 
or CD11c+ Bst2+ plasmacytoid DCs are shown. (n=3, representative of 3 independent 
experiments).  
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Figure 11. CD8α+ DCs express the highest level of the T. gondii sensor TLR11. 
Listed immune cells were sort-purified from 129S6/SvEV wild-type mice, harvested for 
RNA, and analyzed for the expression of TLR11 by quantitative RT-PCR (n=3). All P-
values compare CD8α+ DCs to indicated population. Data are represented as mean +/- 
standard deviation. Not significant (ns): P>0.05, *: 0.01<P<0.05, **: 0.001<P<0.01. 
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Figure 12. CD8α+ DCs produce IL-12, but not IL-23, in response to T. gondii 
infection. (A-C) CD8α+ DCs were sort-purified from T. gondii infected 129S6/SvEV 
wild-type mice on days 0 and 3 after infection, harvested for RNA, and analyzed for the 
expression of cytokine chains by qRT-PCR. Two uninfected and three infected spleens 
were pooled prior to the sort. As positive and negative controls for qRT-PCR, cDNA 
from total splenic CD11c+ cells, the macrophage cell line J774, and total kidney lysate 
were also analyzed. IL-23p19 +ctrl = J774 cDNA, -ctrl = Kidney cDNA; IL-12p35 +ctrl 
= CD11c+ cDNA, -ctrl = J774 cDNA; IL-12/23p40 +ctrl = CD11c+ cDNA, -ctrl = J774 
cDNA. Data are represented as mean +/- standard deviation. Not significant (ns): P>0.05, 
**: 0.001<P<0.01. 
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Figure 13. Administration of IL-12 rescues Batf3-deficient mice during T. gondii 
infection. 129S6/SvEV mice were infected with T. gondii and injected with saline or 
0.5µg of recombinant murine IL-12 on days 0, 1, 2, 3, and 4 after infection. (A) Survival 
data from infected mice (WT: solid black line; WT + IL-12: solid red line; Batf3-/-: 
dashed black line; Batf3-/- + IL-12: dashed red line) (n=3-5, representative of 3 
independent experiments). (B) Combined parasite burden from whole body in vivo 
bioluminescence imaging of infected mice (WT: black squares; WT + IL-12: red squares; 
Batf3-/-: black triangles; Batf3-/- + IL-12: red triangles) from 2 independent experiments 
(n=3-8 at each time-point, representative of 4 independent experiments). Data are 
represented as mean +/- standard deviation. (C) Representative bioluminescence images 
of infected mice throughout the course of infection. *: 0.01<P<0.05, **: 0.001<P<0.01, 
***: P<0.001. 
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Figure 14. Batf3-/- NK cells can produce IFNγ in vitro in response to IL-12 and IL-18. 
129S6/SvEV wild-type and Batf3-/- spleens were incubated in IL-12 and IL-18 for 4 
hours. NK cells were identified using DX5 staining, and stained for intracellular IFNγ. 
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Figure 15. Administration of IL-12 restores IFNγ production in Batf3-deficient mice 
during T. gondii infection. 129S6/SvEV mice were infected with T. gondii and injected 
with saline or 0.5µg of recombinant murine IL-12 on days 0, 1, 2, 3, and 4 after infection. 
(A) Serum levels of IFNγ on day 4 after infection (n=4-5). (B-D) Absolute numbers of 
IFNγ-positive NK (B), CD4+ T (C), and CD8+ T (D) cells in the spleen directly ex vivo on 
day 3 after infection as measured by intracellular cytokine staining (n=3). (A-D) 
Horizontal lines represent the geometric mean. Not significant (ns): P>0.05, *: 
0.01<P<0.05, **: 0.001<P<0.01, ***: P<0.001. 
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Figure 16. CD8α+ dendritic cells are the only cells whose IL-12 production is 
protective against acute T. gondii infection. BALB/c chimeras and control non-
chimeric mice were infected with T. gondii and monitored for survival (A) and parasite 
burden (B-C). (A) Survival data from non-chimeric wild-type (black line) and Batf3-/- 
(red line) mice were compared to lethally irradiated recipients which received only wild-
type (purple line) or Batf3-/- (green line) BM, or a 1:1 mixture of wild-type with Batf3-/- 
BM (orange line) or IL-12p35-/- with Batf3-/- BM (blue line) (n=5-6, representative of 2 
independent experiments). Parasite burden (B) and representative images (C) on day 7 
after infection from the groups in (A). (B) Horizontal lines represent the geometric mean. 
(D) Mixed BM chimeras were analyzed after re-constitution to determine chimerism. 
Blood from BALB/c BM chimeras was analyzed by quantitative RT-PCR. The 
contribution from different donor BM was determined using the male Y chromosome 
gene Zfy as a marker. Data are represented as mean +/- standard deviation. **: 
0.001<P<0.01, ***: P<0.001. 
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Figure 17. Mice re-constituted with a 1:1 mixture of Batf3-/- plus IL-12p35-/- bone 
marrow are unable to control T. gondii burden. (A) Parasite burden from C57BL/6 
BM chimera experiment is shown. Non-chimeric C57BL/6 WT and Batf3-/- mice were 
compared with lethally irradiated WT C57BL/6 recipients who were given either WT, 
Batf3-/-, or IL-12p35-/- BM, or a 1:1 mixture of WT plus Batf3-/-, WT plus IL-12p35-/-, or 
Batf3-/- plus IL-12p35-/- BM. Whole body in vivo bioluminescence imaging was done on 
day 7 after infection (n=4-6, data representative of 2 independent experiments). 
Horizontal lines represent the geometric mean. (B) Mixed BM chimeras were analyzed 
after re-constitution to determine chimerism. Blood from C57BL/6 BM chimeras was 
analyzed by flow cytometry. The contribution from different donor BM was determined 
using the congenic markers CD45.1 and CD45.2. **: 0.001<P<0.01, ***: P<0.001. 
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CHAPTER 6 
IL-12 Bypasses the Block in CD8α+ DC Development in Batf3-/- Mice 
 
Administration of IL-12 to T. gondii infected Batf3-/- mice restores CD8α+ DCs 
While further characterizing the expansion of CD8α+ DCs in T. gondii-infected 
wild-type animals, we made the surprising discovery that exogenous IL-12 could rescue 
the development of CD8α+ DCs in Batf3-/- mice (Fig. 18). In this experiment, wild-type 
and Batf3-/- animals were infected with T. gondii, and half the animals were treated with 
IL-12 for the first five days of infection. As shown previously, CD8α+ DCs expanded in 
wild-type animals in response to infection, while they were absent in Batf3-/- mice before 
and during infection (Fig. 18 A). Administration of IL-12 increased the percentage and 
absolute numbers of CD8α+ DCs in wild-type mice on day 3 after infection. Surprisingly, 
infected Batf3-/- mice that received exogenous IL-12 now acquired a splenic DC subset 
that displayed hallmarks of the CD8α+ DC on both day 3 and 7 after infection (Fig. 18, A 
and B). It is important to note that the markers used for identification of CD8α+ DCs in 
this experiment were CD103 and CD8α. In contrast, CD11b+ DC numbers were 
comparable in all mice, and remained unchanged (Fig. 18 C). Thus, IL-12 administration 
during T. gondii infection bypasses the block in development of CD8α+ DCs in Batf3-/- 
mice. 
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IL-12 administration in the absence of T. gondii infection can restore CD8α+ DCs in 
Batf3-/- mice 
In order to determine if the restoration of CD8α+ DCs could be achieved by IL-12 
administration alone, or required both IL-12 and T. gondii infection, we treated 
uninfected wild-type and Batf3-/- mice with IL-12 for 3 days, and analyzed the spleens by 
flow cytometry. IL-12 administration in the absence of T. gondii infection was sufficient 
to restore the CD8α+ DC subset in Batf3-/- mice (Fig. 19, A and B). This finding was 
independent of the genetic background, as it occurred in all strains tested, namely 
BALB/c, C57BL/6 and 129S6/SvEV. Moreover, the effect was specific for the CD8α+ 
DC compartment, since CD11b+ DC numbers were unaffected by treatment (Fig. 19 C).  
To further confirm the identity of the restored cells as CD8α+ DCs, we added an 
additional antibody against DEC205. By comparing the different strains of mice, we 
found a discrepancy in antibody staining of CD8α+ DCs using DEC205 versus CD103 
(Fig. 19 A). Both markers are thought to be expressed exclusively on classic CD8α+ DCs, 
as opposed to the newly described CD8α+ CX3CR1+ subset (Bar-On et al., 2010). 
However, in our hands, CD8α+ DCs uniformly expressed the multilectin receptor 
DEC205, but not the integrin CD103. IL-12 administration consistently increased CD103 
expression on the DEC205+ CD8α+ DCs, while untreated DEC205+ CD8α+ DCs 
expressed a range of CD103 that varied from experiment to experiment and between the 
different strains of mice. Therefore, DEC205 was chosen as a more specific surface 
marker to positively identify CD8α+ DCs for future experiments, and any reference to 
CD8α+ DCs will specifically delineate CD8α+ DEC205+ cells.  
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In addition, we formally ruled out the possibility that another cell type was 
acquiring these “DC markers” and falling within the CD8α+ DC gate upon IL-12 
treatment. Restored CD8α+ DCs in Batf3-/- mice were negative for the B cell marker 
B220, the T cell marker CD3, and the NK cell marker NKp46 (Fig. 20), suggesting that 
these cells were not B, T, or NK cells that had acquired “DC markers” upon IL-12 
treatment.  
 
CD8α+ DCs are present in normal numbers in IL-12-deficient mice 
 Based on this novel finding that IL-12 may play a role in CD8α+ DC 
development, we examined CD8α+ DCs during steady state conditions in IL-12p35-/- 
mice. These mice have not been reported to have a defect in the dendritic cell 
compartment, although we could not find a published report specifically analyzing DCs 
subsets. Wild-type and IL-12p35-/- mice had comparable percentages of CD8α+ DCs in 
the spleen (Fig. 21), suggesting that IL-12 is not required for normal development or 
maintenance of this population in the steady state. 
 
The restoration of Batf3-/- CD8α+ DCs by IL-12 is IFNγ-dependent 
 IL-12 is known to induce IFNγ production, and many of its effects are mediated 
by IFNγ (Trinchieri, 2003). Therefore, in order to understand the underlying mechanism 
for the reappearance of CD8α+ DCs, we evaluated a requirement for IFNγ by using the 
IFNγ-blocking antibody H22. H22 treatment completely blocked the IL-12-induced 
development of CD8α+ DCs in Batf3-/- mice in vivo (Fig. 22, A and B). In contrast, 
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CD11b+ DC numbers were not significantly altered by H22 treatment (Fig. 22 C). Thus, 
IL-12 induces the development of CD8α+ DCs in Batf3-/- mice via IFNγ.  
 
NK, B and T Cells are not required for the restoration of CD8α+ DCs in Batf3-/- mice 
after IL-12 treatment 
 IFNγ can be produced by a number of cell types, although NK cells are thought to 
be the major producers of IFNγ in response to IL-12 (Trinchieri, 2003). In order to 
determine if NK cells were required for the IL-12/IFNγ-mediated generation of CD8α+ 
DCs in Batf3-/- mice, we treated the mice with the anti-NK1.1 antibody PK136 to deplete 
NK cells in vivo. NK cell depletion was confirmed using the NK-specific antibodies DX5 
and NKp46. PK136 effectively depleted NK cells by approximately 10-fold on day 6 
after antibody treatment (Fig. 23, A and B). However, the IL-12-induced restoration of 
CD8α+ DCs in Batf3-/- mice was unaffected by NK cell depletion (Fig. 24, A and B).  
 T cells and B cells can also produce IFNγ in response to inflammation as well as 
antigen encounter (Lertmemongkolchai et al., 2001; Harris et al., 2005). We therefore 
hypothesized that T and/or B cells could be the source of “by-stander” antigen-
independent IFNγ in the Batf3-/- mice following IL-12 treatment. To test this hypothesis, 
we used RAG-deficient mice that are missing both B and T cells due to a developmental 
block in the antigen-receptor recombination machinery. IL-12-induced CD8α+ DC 
restoration was not abrogated in the absence of B and T cells in Rag/Batf3-/- mice (Fig. 
24, A and C), suggesting that B and T cells are dispensable for this effect. 
 Finally, considering that all lymphocytes are able to produce IFNγ, we wanted to 
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exclude the possibility that one subset, meaning B, T, or NK cells, could compensate for 
the absence of the other. Therefore, we combined NK depletion with the use of RAG-
deficient mice. NK cell depletion was again confirmed on the day of harvest using DX5 
and NKp46 antibodies (Fig. 23, A and C). IL-12 treatment could restore CD8α+ DC 
development in Rag/Batf3-/- animals treated with PK136 (Fig. 24, A and C), suggesting 
that NK cells, B cells, and T cells are not required. This result leaves a few hypotheses 
open. First, NK cell depletion was not 100% efficient, especially in mice that received 
exogenous IL-12 (Fig. 23). It is possible that the remaining NK cells are producing 
sufficient amounts of IFNγ for restoration of CD8α+ DCs after IL-12 treatment. 
Alternatively, it is possible that other cells belonging to the innate compartment can 
respond to IL-12 treatment and produce IFNγ in vivo (Ohteki et al., 1999; Puddu et al., 
1997; Munder et al., 1998). These questions will be addressed in future work. 
 
Time-course of CD8α+ DC reappearance in response to IL-12 treatment in vivo 
 To understand the effect of IL-12 on CD8α+ DC development in Batf3-/- mice, we 
performed a time-course experiment, evaluating how quickly CD8α+ DCs appear in the 
spleen, and how long they remain. CD8α+ DCs have a relatively short half-life in the 
periphery, and are constantly replenished from precursors present in the spleen and bone 
marrow (Kamath et al., 2000; Kamath et al., 2002). Mice were treated with a single dose 
of IL-12, and analyzed from day one to seven by flow cytometry. Absolute numbers of 
CD8α+ DCs in wild-type mice were fairly constant throughout the course of the 
experiment (Fig. 25). In Batf3-/- mice, CD8α+ DCs began to appear on day 2 after IL-12 
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treatment, reaching the peak numbers on day 4, with a few CD8α+ DCs still detectable as 
late as day 7. This quick wave of appearance in the spleen suggests that IL-12 may be 
acting on a local progenitor population, such as the splenic pre-cDCs.  
 
Analysis of CD8α+ DC precursors in the spleen 
 For this reason, we decided to carefully analyze splenic progenitors in terms of 
the percentage and absolute numbers of pre-cDCs following IL-12 administration. Pre-
cDCs are the immediate precursors of cDCs, and can be identified as MHCII- CD11c+ 
B220- cells that are positive for Flt3 and intermediate for SIRPα (Fig. 26) (Naik et al., 
2006). In the steady state, splenic pre-cDC numbers were comparable between wild-type 
and Batf3-/- mice. IL-12 treatment did not substantially alter pre-cDC numbers, although 
this experiment needs to be repeated with larger groups of mice to perform statistical 
analysis. From this preliminary experiment, it appears that the percentage of pre-cDCs is 
slightly reduced by IL-12 treatment (Fig. 26 A), while the absolute numbers tended to be 
increased (Fig. 26 B). However, IL-12 administration increases the cellularity of the 
spleen in wild-type and Batf3-/- mice, making it difficult to interpret data where 
percentages are unchanged or reduced, while absolute numbers are increased. Therefore, 
it is important to normalize pre-cDC cell numbers based on the spleen size, and 
determine the number of pre-cDCs per million splenocytes (Fig. 26 C). Using this 
analysis, it appears as though IL-12 treatment is not preferentially causing expansion of 
pre-cDCs in wild-type or Batf3-/- mice. 
 We next used an additional marker, CD24, to monitor CD8α+ DC maturation in 
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the presence of IL-12. CD24 can be used to identify CD8α+ DCs both in vivo and in 
vitro. When CD24+ cells were analyzed for expression of DEC205, we saw that this 
population was in fact heterogenous for DEC205 staining (W KC, unpublished) and (Fig. 
27). Using DEC205 as a marker of maturation, we could discern roughly 3 
subpopulations: DEC205 low and intermediate expressing cells, which are presumably 
immediate CD8α+ DC precursors, and DEC205 high expressing cells, which correspond 
to the mature CD8α+ DCs. Treatment of wild-type mice with IL-12 shifted all the CD24+ 
DCs to the subset expressing high levels of DEC205, which suggests that IL-12 is 
causing maturation of the pre-CD8α+ DCs in the spleen. In Batf3-/- mice, very few cells 
fall within the CD24+ gate, and most are low or intermediate for DEC205, consistent with 
a very late block in CD8α+ DC development in these mice (W KC, unpublished). IL-12 
treatment substantially increased the percentage of cells within the CD24+ gate, and 
induced their maturation as measured by high expression of DEC205. Thus, it seems as 
though IL-12 is acting on the very late stage of CD8α+ DC development to cause 
maturation of splenic progenitors in Batf3-/- mice. 
 
Candidate transcription factors Batf and IRF-8 are not induced in Batf3-/- IL-12-
treated CD8α+ DCs 
 Batf and Batf3 are members of the AP-1 transcription factor family. Batf-deficient 
mice have defects in Th17 differentiation and in B cell class-switch recombination 
(Schraml et al., 2009; Ise et al., 2011). However, these two AP-1 transcription factors are 
likely paralogous, and share significant homology. In addition, in vitro experiments have 
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shown that Batf and Batf3 are interchangeable in CD8α+ DC development, Th17 
generation, and B cell class-switch recombination (W Ise, W KC, T Murphy, unpublished 
data). Thus, we hypothesized that Batf could complement for Batf3 in CD8α+ DC 
development in vivo, and we are in the process of generating Batf/Batf3-double deficient 
mice to directly ask this question. In the interim, we asked if Batf was up-regulated in IL-
12-restored CD8α+ DCs in Batf3-/- mice (Fig. 28).  
Batf3 is highly expressed in wild-type untreated and IL-12-treated CD8α+ DCs, as 
expected, and is absent from the IL-12-treated Batf3-/- CD8α+ DCs (Fig. 28 A). In 
addition, the Batf3 paralog Batf is expressed at comparable levels in all three DC 
populations, which is approximately 2-fold less than activated B cells, and is not induced 
by IL-12 treatment (Fig. 28 B).  
We also looked for induction of the transcription factor IRF-8, which is important 
in CD8α+ DC development as discussed in the introduction (Aliberti et al., 2003). IRF-8 
appears to be induced upon IL-12-treatment of wild-type CD8α+ DCs, but is comparable 
between untreated wild-type and IL-12-treated Batf3-/- CD8α+ DCs (Fig. 28 C). From this 
data, it was still unclear if either Batf or IRF-8 could be compensating for the absence of 
Batf3 in CD8α+ DC development. Thus, we moved from this candidate-based approach to 
global expression analysis using microarrays. 
 
Microarray analysis of restored CD8α+ DCs from Batf3-/- mice 
 The restored CD8α+ DCs in Batf3-/- mice correctly expressed a number of surface 
markers used to identify these cells. Nevertheless, we are only beginning to understand 
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the unique capabilities of CD8α+ DCs and the host of genes required for their 
development and function. We therefore performed microarray analysis of IL-12-restored 
CD8α+ DCs from Batf3-/- animals to determine the expression profile of these cells and 
compare them to wild-type CD8α+ DCs.  
Global comparison of genes expressed in CD8α+ DCs from IL-12-treated wild-
type and Batf3-/- mice revealed very few differences (Fig. 29 A), with only 206 genes 
displaying a greater than 4-fold difference between the samples.  This high degree of 
similarity suggests that the restored CD8α+ DCs in Batf3-/- mice are comparable to their 
wild-type counterparts in global gene expression. There were a few genes, such as 
germinal center B-cell expressed transcript 2 (GCET2), that seemed to be strictly Batf3-
dependent and could not be restored with IL-12 treatment. However, none of these genes 
have yet been characterized in CD8α+ DCs. In addition, wild-type CD8α+ DCs from 
untreated and IL-12-treated mice were nearly identical in gene expression (Fig. 29 B), 
with only 70 genes displaying a greater than 4-fold difference between the samples. The 
few genes that significantly varied between wild-type untreated and IL-12-treated CD8α+ 
DCs were X- or Y-chromosomes specific, which could be attributed to the sex of the 
mice used for the microarray analysis. Finally, we compared Batf3-/- IL-12-restored 
CD8α+ DCs to wild-type CD8α- DCs (Fig. 29 C). Over fourteen-hundred genes 
displayed a greater than 4-fold difference between these samples, clearly demonstrating 
that these two population were disparate. Overall, the microarray data strongly suggests 
that the restored CD8α+ DCs in Batf3-/- mice are extremely similar to wild-type CD8α+ 
DCs in global gene expression. 
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CD8α+ DCs are restored by T. gondii infection in Batf3-/- mice 
 As shown in Figure 6 A, significant levels of IL-12 are induced in T. gondii-
infected wild-type mice as measured in the serum starting at day 4 after infection. In 
addition, intracellular IL-12p40 can be measured within CD8α+ DCs as early as 3 days 
after infection in wild-type mice (Fig. 9), and is necessary for protective immunity 
against T. gondii as demonstrated in chapter 5. However, other cell types are capable of 
producing IL-12 in Batf3-/- mice, and IL-12p40 can be detected in the serum starting at 
day 5 after infection (Fig. 6 A). Although this delayed and reduced production of IL-12 is 
not sufficient to protect mice against T. gondii, we reasoned that it may be sufficient to 
restore the CD8α+ DC population in Batf3-/- mice, similar to exogenous IL-12. However, 
the data in Figure 7 shows an absence of CD8α+ DCs in infected Batf3-/- mice at all time-
points examined. Yet upon closer inspection of Figure 7, we discerned an expansion of 
CD8α+ CD103- DCs, especially by day 7 after infection. At that time, we were using the 
surface marker CD103 to distinguish classic CD8α+ DCs from the CD8α+ CX3CR1+ 
subset. As mentioned above, we later determined that DEC205 is a more faithful marker 
of CD8α+DCs, while CD103 expression can be variable. Therefore, we repeated the 
experiment using DEC205 as an additional marker to test if endogenous IL-12 could 
restore classic CD8α+ DCs in infected Batf3-/- mice.  
Wild-type and Batf3-/- mice were infected with T. gondii and examined for the 
development of CD8α+ DCs in the spleen on day 7 (Fig. 30). A similar trend, as observed 
with exogenous IL-12 treatment (Fig. 19), could be seen following T. gondii infection. 
CD8α+ DCs expanded in response to T. gondii infection in 129S6/SvEV wild-type mice 
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(Fig. 30), as seen in Figure 7. In addition, CD8α+ DCs expanded in infected C57BL/6 
wild-type mice, but not in BALB/c wild-type mice, although the groups in each case were 
not large enough to determine statistical significance. In Batf3-/- mice, CD8α+ DCs, as 
identified by co-expression of DEC205, were restored on all three genetic strains tested 
upon T. gondii infection (Fig. 30). Infection also restored absolute numbers of CD8α+ 
DCs in Batf3-/- mice, although to varying degrees depending on the strain (Fig. 30 B). In 
addition, if we only consider CD103 expression, the data from Figure 7 and Figure 30 
would be consistent: there is no CD8α+ CD103+ DC subset in infected 129S6/SvEV 
Batf3-/- mice in either Figure 7 or Figure 30. Thus, by adding the more faithful marker 
DEC205 to our analysis, we were able to demonstrate restoration of CD8α+ DCs by T. 
gondii infection in Batf3-/- mice.  
 
T. gondii-mediated restoration of CD8α+ DCs in Batf3-/- mice is IFNγ-dependent 
To further prove that infection-mediated restoration of CD8α+ DCs  is due to IL-
12 and IFNγ produced during the course of infection, we treated mice with the IFNγ-
blocking antibody H22 (Fig. 31). H22 treatment effectively blocked the restoration of 
CD8α+ DCs in T. gondii-infected Batf3-/- mice, demonstrating a requirement for IFNγ in 
this process in vivo. Future experiments using IL-12-blocking antibody will more 
definitively demonstrate a role for endogenous IL-12 in CD8α+ DC restoration in 
infected Batf3-/- mice.  
In lieu of that, we tested the response of BALB/c IL-12p35-/- mice to T. gondii 
infection. We hypothesized that if endogenous IL-12 produced in the course of infection 
65
was causing expansion of the CD8α+ DCs in wild-type mice, then perhaps this response 
would be absent in IL-12p35-/- animals (Fig. 32). However, the result of this experiment 
was difficult to interpret. While the percentage of CD8α+ DCs increased with infection in 
both wild-type and IL-12p35-/- mice, the absolute numbers of these cells appeared to be 
unchanged. This can be attributed to the genetic background of the mice used. As 
discussed above, CD8α+ DCs do not expand in response to infection in wild-type 
BALB/c mice, unlike their 129S6/SvEV and C57BL/6 counterparts (Fig. 30). Therefore, 
we could not conclude if endogenous IL-12 is required for CD8α+ DC expansion in wild-
type mice during T. gondii infection. One possible approach is to breed Batf3-/- mice to 
IL-12p35-/- mice, and test the re-appearance of CD8α+ DCs in response to infection. As 
seen in Figure 30, the restoration of CD8α+ DCs in Batf3-/- mice is consistently seen in all 
genetic backgrounds tested. Thus, if CD8α+ DCs are not restored with T. gondii infection 
in Batf3/IL-12p35-double deficient mice, we would be able to conclude that endogenous 
IL-12 is required for restoration of CD8α+ DCs during infection. 
   
Restored Batf3-/- CD8α+ DCs can cross-present necrotic cell antigens in vivo 
 CD8α+ DCs possess an enhanced ability to cross-present exogenous antigen on 
MHCI molecules to prime CD8+ T cell responses in vivo (Hildner et al., 2008). Extensive 
research on CD8α+ DCs has been focused on understanding the cellular components that 
allow this particular cell to excel at cross-presentation, and we are only beginning to 
understand the underlying mechanisms (Lin et al., 2008). To determine if the IL-12-
restored CD8α+ DCs were capable of cross-presentation, we examined their ability to 
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cross-present necrotic-cell associated antigens in vivo (Fig. 33).  
OT-I transgenic T cells were CFSE labeled and injected into wild-type or Batf3-/- 
mice intra-peritoneally. OT-I T cells are specific for the model antigen OVA, and are 
used as the responder cells in this assay. Carboxy-Fluorescein diacetate Succinimyidyl 
Ester (CFDA-SE) is a highly permeable compound that enters cells and is converted to a 
green fluorescent dye (CFSE). CFSE-labeling of cells is routinely used to follow cell 
proliferation by flow cytometry, since the amount of CFSE within cells is halved with 
each division.  
Antigen was provided to the recipient wild-type and Batf3-/- animals three days 
later in the form of OVA-pulsed irradiated MHCI-/- splenocytes. MHCI-/- splenocytes 
were used to ensure that direct presentation of OVA to OT-I T cells cannot occur. MHCI-
/- splenocytes were OVA-loaded by osmotic shock and subsequently irradiated to induce 
cell death. Thus, in order to prime CD8+ T cell responses, exogenous OVA must be taken 
up and processed by the recipient’s MHCI-sufficient DCs via cross-presentation. Antigen 
delivery within the context of dead/dying cells mimics more physiologic conditions likely 
to occur during cross-presentation, such as virally infected cells dying in the course of 
infection. The recently identified CLEC9A, which is exclusively expressed on CD8α+ 
DCs, is most likely responsible for the uptake of dead/dying MHCI-/- splenocytes (Sancho 
et al., 2009).  
Finally, recipient mice were harvested 3 days after antigen administration and 
analyzed by flow cytometry. As a negative control, un-pulsed MHCI-/- splenocytes were 
injected. OT-I T cells in these control mice did not proliferate, as demonstrated by a 
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failure to dilute CFSE (Fig. 33 A). OT-I T cells injected into wild-type recipients given 
OVA-pulsed MHCI-/- splenocytes completely diluted CFSE, indicating that all the cells 
had proliferated (Fig. 33 A). In addition, the absolute number of OT-I T cells recovered 
increased, also indicating proliferation (Fig. 33 B).  
Batf3-/- mice cannot cross-present necrotic-cell associated antigen due to the 
absence of CD8α+ DCs, as previously shown in vitro (Hildner et al., 2008). We now 
extend this finding to in vivo cross-presentation. OT-I T cells injected into Batf3-/- mice 
and given antigen did not proliferate as measured by CFSE dilution and absolute cell 
numbers (Fig. 33 A). Interestingly, high doses of antigen can induce OT-I T cell 
proliferation in Batf3-/- mice in vivo (Fig. 34 B), suggesting that at high doses of antigen, 
other cells that are less efficient at cross-presentation can compensate for the absence of 
CD8α+ DCs. However, such high doses of antigen are unlikely to occur in physiologic 
settings, highlighting the importance of CD8α+ DCs in CD8+ T cell priming.  
Since IL-12 treatment restores the CD8α+ DC population in Batf3-/- mice, we 
asked if in vivo antigen cross-presentation was also restored with IL-12 treatment (Fig. 
33). To ensure that IL-12 alone was not sufficient to cause antigen-independent OT-I T 
cell proliferation, we treated mice given unpulsed MHCI-/- splenocytes with IL-12. IL-12 
treatment in the absence of antigen did not cause proliferation of OT-I T cells (Fig. 33 A). 
In addition, OT-I proliferation was comparable between wild-type untreated and IL-12 
treated mice. However, IL-12 treated Batf3-/- mice now re-gained the ability to induce 
OT-I proliferation in response to exogenous OVA in vivo. This result suggests that the 
restored CD8α+ DCs in IL-12 treated Batf3-/- mice were functional and could cross-
68
present exogenous necrotic-cell associated antigen as efficiently as their wild-type 
counterparts. However, it is still possible that IL-12 is having additional effects in vivo 
that could confound these conclusions. For example, IL-12 could be enhancing the ability 
of other cells to cross-present. An in vitro cross-presentation assay performed with sorted 
CD8α+ DCs from IL-12 treated Batf3-/- mice must be done to completely rule out these 
possibilities, and to demonstrate the cross-presentation ability of the restored CD8α+ DCs 
on a per cell basis. 
 
Restored Batf3-/- CD8α+ DCs can produce IL-12 in response to T. gondii infection in 
vivo 
 To determine if restored CD8α+ DCs in Batf3-/- mice could function in the context 
of T. gondii infection, we examined intracellular IL-12p40 levels in these cells on days 3 
and 7 after infection (Fig. 35). As discussed above, wild-type CD8α+ DCs express IL-
12p40 as early as day 3 after infection, and continue to express this cytokine on day 7. 
IL-12 treated wild-type CD8α+ DCs, on the other hand, do not express significant levels 
of IL-12p40 on day 3 after infection, but begin to express IL-12p40 on day 7. As seen in 
Figure 34, IL-12-treated wild-type mice have lower parasite burden as compared to 
untreated wild-type mice, which could account for the delayed kinetics of IL-12p40 
production by the CD8α+ DCs in IL-12-treated mice.  
We next examined IL-12-treated Batf3-/- CD8α+ DCs in T. gondii-infected mice 
(Fig. 35). Three days after infection, there is no IL-12p40 being produced by the restored 
Batf3-/- CD8α+ DCs, similar to their IL-12 treated wild-type counterparts. However, on 
69
day 7 after infection, approximately 25% of CD8α+ DCs in both wild-type and Batf3-/- 
mice are positive for IL-12p40. In summary, while the kinetics of endogenous IL-12 
production by CD8α+ DCs is slower in IL-12-treated T. gondii infected mice, both wild-
type and Batf3-/- CD8α+ DCs produce IL-12 7 days after infection.  
 
Restored Batf3-/- CD8α+ DCs can prime CD8+ T cells to T. gondii-specific antigens in 
vivo 
 In addition to producing IL-12, CD8α+ DCs are required for priming T. gondii-
specific CD8+ T cells during in vivo infection (Fig. 3). Therefore, we next asked if the IL-
12-restored CD8α+ DCs in Batf3-/- mice could prime CD8+ T cells in vivo (Fig. 36). 
Wild-type and Batf3-/- animals were infected with T. gondii and treated with IL-12 during 
the first five days of infection, then harvested on day 7 for analysis. To test if T cells were 
primed in vivo, we cultured splenocytes from the infected animals overnight with peptide 
from the T. gondii-derived protein GRA4. After re-stimulation, T cells were analyzed for 
IFNγ production by intracellular cytokine staining. Wild-type T cells could produce IFNγ 
in response to the peptide from both untreated and IL-12 treated mice (Fig. 35). Batf3-/- T 
cells from mice that did not receive IL-12 could not produce IFNγ after in vitro re-
stimulation, consistent with Figure 3. However, T cells from Batf3-/- IL-12 treated mice 
now regained the ability to produce IFNγ in response to the GRA4 peptide. This data 
suggests that IL-12-restored CD8α+ DCs in Batf3-/- mice can present T. gondii-derived 
antigen to CD8+ T cells and prime the adaptive immune response.  However, as with the 
in vivo cross-presentation assay above, the priming ability of the IL-12-restored CD8α+ 
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DCs needs to be tested on a per cell basis in vitro to rule out other effects of IL-12 
treatment during in vivo priming. 
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Figure 18. IL-12 administration rescues CD8α+ DC development in infected Batf3-/- 
mice. 129S6/SvEv wild-type and Batf3-/- mice were infected with T. gondii and injected 
with saline or 0.5µg of recombinant murine IL-12 on days 0, 1, 2, 3, and 4 after infection. 
Animals were sacrificed on days 3 and 7 after infection, and analyzed by flow cytometry 
(n=3). (A) Representative FACS plots gated on Aqua-negative, MHCII+, CD11c+ 
conventional dendritic cells. (B and C) Absolute numbers of CD8α+ CD103+ DCs (B) 
and CD11b+ DCs (C) in the spleen of wild-type and Batf3-/- mice on days 3 and 7 of 
infection. (B, C) Data are represented as mean +/- standard deviation. 
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Figure 19. IL-12 treatment restores CD8α+ DC development in Batf3-/- mice. Wild-
type (black bars) and Batf3-/- (white bars) mice were given exogenous IL-12 and 
harvested for analysis of the splenic conventional DC compartment. 129S6/SvEV and 
C57BL/6 mice were treated on days 0, 1, and 2, and harvested on day 3. BALB/c mice 
were treated on days 0, 1, 2, 3 and 4, and harvested on day 5. (A) Representative FACS 
plots of the MHCII+ CD11c+ DCs. (B and C) Absolute numbers of CD8α+ DCs (B) and 
CD11b+ DCs (C). Data are represented as mean +/- standard deviation. Not significant 
(ns): P>0.05, *: 0.01<P<0.05, **: 0.001<P<0.01. 
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Figure 20. CD8α+ DCs in the spleen of IL-12-treated Batf3-/- mice do not express the 
B cells marker B220, the T cell marker CD3, or the NK cell marker NKp46. 
129S6/SvEV wild-type and Batf3-/- mice were treated with IL-12 on days 0, 1, and 2, and 
harvested on day 3 for FACS analysis. Representative FACS plots gated on MHCII+ 
CD11c+ DCs are shown. 
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Figure 21. Mice deficient in IL-12 can develop splenic CD8α+ DCs in the steady 
state. BALB/c wild-type and IL-12p35-/- mice were harvested for analysis of the splenic 
conventional DC compartment. (A) Representative FACS plots gated on MHCII+ 
CD11c+ cells are shown. (B and C) Absolute numbers of CD8α+ DCs (B), or the number 
of CD8α+ DC per million splenocytes (C). Data are represented as mean +/- standard 
deviation. Not significant (ns): P>0.05. 
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Figure 22. IL-12-mediated restoration of CD8α+ DCs in Batf3-/- mice is IFNγ-
dependent. BALB/c wild-type and Batf3-/- mice were treated with control PIP or anti-
IFNγ blocking antibody H22 on days -2 and +1, given IL-12 on day 0, and harvested on 
day 3 for analysis of the splenic conventional DC compartment. (A) Representative 
FACS plots of MHCII+ CD11c+ DCs. (B and C) Absolute numbers of CD8α+ DCs (B) 
and CD11b+ DCs (C). Data are represented as mean +/- standard deviation. 
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Figure 23. Efficiency of NK cell depletion using anti-NK1.1 PK136 antibody. 
C57BL/6 wild-type, Batf3-/-, Rag-/-, and Rag/Batf3-/- mice were treated with 200µg of NK 
cell depleting antibody PK136 on day -3, followed by 100µg on day 0, and in addition 
were treated with IL-12 on day 0. All mice were harvested on day 3 and analyzed for NK 
cell depletion efficiency. (A) Representative FACS plots of splenocytes. (B and C) 
Absolute numbers of NK cells in all mice. Data are represented as mean +/- standard 
deviation. 
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Figure 25. Time course of CD8α+ DC development in IL-12-treated Batf3-/- mice. 
BALB/c wild-type and Batf3-/- mice were treated with a single dose of IL-12, and 
harvested 1 to 7 days later for analysis of spleen DCs. Absolute numbers of CD8α+ DCs 
are shown. Data are represented as mean +/- standard deviation. 
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Figure 26. Pre-cDC numbers in the spleen are unchanged with IL-12 treatment. 
C57BL/6 wild-type and Batf3-/- mice were treated with a single dose of IL-12 on day 0, 
and sacrificed on day 3 for analysis of the pre-cDC in the spleen. (A) Representative 
FACS plots gated on MHCII+ CD11c+ B220- cells are shown. (B and C) Absolute 
numbers of pre-cDCs (B), or the number of pre-cDCs per million splenocytes. Data are 
represented as mean +/- standard deviation. 
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Figure 27. IL-12 treatment causes upregulation of DEC205 on CD8α+ DC 
precursors in both wild-type and Batf3-/- mice. C57BL/6 wild-type and Batf3-/- mice 
treated on day 0 with IL-12 were analyzed for various CD8α+ DC markers. 
Representative FACS plots gated on MHCII+ CD11c+ B220- cells are shown.  
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Figure 28. Batf3-/- IL-12-restored CD8α+ DCs express normal levels of the 
transcription factors Batf and IRF-8. C57BL/6 wild-type and Batf3-/- mice were treated 
with IL-12 on days 0, 1, and 2, and harvested on day 3 for sort purification of CD8α+ 
DCs. Shown is relative expression of Batf3 (A), Batf (B), and IRF-8 (C), as normalized 
against HPRT. Controls were as follows: Batf: +ctrl = WT LPS activated B cells, -ctrl = 
Batf-/- LPS activated B cells; IRF-8: +ctrl = in vitro Flt3L-cultured CD8a+ equivalent 
DCs, -ctrl = in vitro Flt3L-cultured CD4+ equivalent DCs. Data are represented as mean 
+/- standard deviation. 
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Figure 30. T. gondii infection restores CD8α+ DC development in Batf3-/- mice. 
129S6/SvEV, C57BL/6 and BALB/c wild-type and Batf3-/- mice were infected with T. 
gondii tachyzoites ip and harvested 7 days after infection for analysis of the splenic 
conventional DC compartment. (A) Representative FACS plots of MHCII+ CD11c+ DCs. 
(B and C) Absolute numbers of CD8α+ DCs (B) and CD11b+ DCs (C). Data are 
represented as mean +/- standard deviation. 
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Figure 31. T. gondii-mediated restoration of CD8α+ DCs in Batf3-/- mice is IFNγ-
dependent. BALB/c wild-type and Batf3-/- mice were treated with control antibody PIP 
or anti-IFNγ blocking antibody H22 on days -1 and +2, infected with T. gondii on day 0, 
and sacrificed for analysis on day 7. (A) Representative FACS plots gated on MHCII+ 
CD11c+ cells are shown. (B) Absolute numbers of CD8α+ DCs are shown. Data are 
represented as mean +/- standard deviation. 
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Figure 32. IL-12p35-/- CD8α+ DCs increase in percentage, but not absolute numbers, 
after T. gondii infection. BALB/c wild-type and IL-12p35-/- mice were infected with T. 
gondii tachyzoites ip, sacrificed on day 7 after infection, and analyzed for the 
composition of the conventional DC compartment. (A) Representative FACS plots gated 
on MHCII+ CD11c+ cells are shown. (B) Absolute numbers of CD8α+ DCs in the spleen 
in naïve and infected mice. Data are represented as mean +/- standard deviation. 
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Figure 33. IL-12 treatment restores cross-presentation in Batf3-/- mice in vivo. 
C57BL/6 wild-type and Batf3-/- mice were analyzed for in vivo cross-presentation of 
necrotic cells. (A) Representative FACS plots gated on CD8+ CD45.1+ OT-I transgenic T 
cells in the left panel, followed by analysis of CFSE dilution in OT-I T cells in the right 
panel. (B) Absolute numbers of OT-I transgenic T cells in the spleen. Data are 
represented as mean +/- standard deviation. 
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Figure 34. In vivo cross-presentation of necrotic cell-associated antigen is severely 
impaired in Batf3-/- mice. C57BL/6 wild-type and Batf3-/- mice were tested for cross-
presentation of MHCI-/- OVA-pulsed splenocytes in vivo. Representative FACS plots are 
shown. 
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Figure 35. IL-12-restored CD8α+ DCs in Batf3-/- mice produce IL-12 in response to 
T. gondii infection in vivo. 129S6/SvEv wild-type and Batf3-/- mice were infected with T. 
gondii and injected with saline or 0.5µg of recombinant murine IL-12 on days 0, 1, 2, 3, 
and 4 after infection. Animals were sacrificed on days 3 and 7 after infection, and 
analyzed by flow cytometry (n=3). Representative FACS plots gated on MHCII+ CD11c+ 
CD8α+ CD103+ DCs are shown. 
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Figure 36. CD8+ T cell priming to T. gondii-derived antigen is restored in infected 
Batf3-/- mice given IL-12. Balb/c wild-type and Batf3-/- mice were sacrificed on day 7 
after infection, and analyzed for CD8+ T cell priming. Shown are absolute numbers of 
IFNγ-positive CD8+ T cells as measured by intracellular cytokine staining after overnight 
re-stimulation of whole splenocytes with the GRA4 peptide (n=5). Not significant (ns): 
P>0.05, **: 0.001<P<0.01. Data are represented as mean +/- standard deviation. 
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CHAPTER 7 
Discussion 
 
CD8α+ DCs are the critical source of IL-12 during T. gondii infection 
The present study identifies a second critical activity for the CD8α+ DC subset 
beyond its recognized role in priming CD8+ T cells responses to viruses. Previously, we 
demonstrated that the CD8α+ dendritic cell was critical in promoting effective CTL 
responses against West Nile virus, and was crucial in that setting for cross-presentation of 
virus-derived antigens involved in immune activation (Hildner et al., 2008). Additionally, 
priming of Sendai virus-specific CD8+ T cells has been shown to be dependent on the 
peripheral cross-presenting CD103+ DC, which is also absent in the Batf3-deficient mice 
(Edelson et al., 2010). Here, we show that priming of CD8+ T cells to endogenous T. 
gondii antigen is also defective in Batf3-deficient mice early after infection. Additionally, 
we demonstrate that the same DC subset provides a critical but distinct function by acting 
as an important early sensor of infection by T. gondii. The inability of mixed chimeras 
generated from bone marrow of IL-12p35-deficient and Batf3-deficient mice to control T. 
gondii infection demonstrates that the CD8α+ DC is the only cell whose IL-12 production 
significantly contributes to reducing pathogen burden during acute infection. Thus, in 
each of these pathogen settings, the CD8α+ DC is unique in its provision of effective 
defense mechanisms, but the mechanisms by which this cell mediates defenses are 
different.  
The role of CD8α+ DCs in protection against T. gondii infection was previously 
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suggested through the observation that this subset was the major cell type to produce IL-
12 in response to intravenous administration of T. gondii antigen STAg (Reis e Sousa et 
al., 1997). Furthermore, CD8α+ DCs express TLR11 at much higher levels than CD8α- 
DCs, neutrophils, and monocytes (Yarovinsky et al., 2005) and (Fig. 11). However, pDCs 
also express TLR11 (Pepper et al., 2008), so that the correlation between sensitivity to 
activation by T. gondii does not exclusively identify the CD8α+ DC as the main 
responder. Thus, no clear evidence previously was able to uniquely identify the CD8α+ 
DC as a cell type required for controlling T. gondii infection in vivo. In addition, while 
TLR11-deficient mice have impaired IL-12 production following infection by T. gondii 
(Yarovinsky et al., 2005), these mice only show a modest change in susceptibility 
compared to the dramatic increase seen in MyD88 knockout mice (Scanga et al., 2002), 
implying that additional sensors for T. gondii infection may exist. One group has reported 
an additional TLR that is responsive to T. gondii, TLR12, and has found that mice 
deficient in both TLR11 and TLR12 are highly susceptible to this infection (A Sher, 
unpublished). Our data strongly demonstrate that the CD8α+ DC is the main cell induced 
to produce IL-12 after acute challenge with T. gondii tachyzoites, which agrees with 
selective expression of TLR11, and potentially other uncharacterized T. gondii-specific 
sensors such as TLR12, by this cell type.  
Several questions still remain. Once the report on TLR12 has been published, it 
will be interesting to investigate the expression of this receptor, and determine if it is also 
highly expressed on CD8α+ DCs. At this time, the nomenclature between TLR11 and 
TLR12 is extremely muddled, and it is difficult to determine the sequence or location of 
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TLR12. What was originally described as TLR11, which responds to T. gondii-profilin 
(Yarovinsky et al., 2005), is now listed as TLR12 in NCBI. In addition, the TLR11 
ortholog in humans is a pseudogene, and there is still a question of how immune 
responses to T. gondii are initiated in humans (Pifer and Yarovinsky, 2011).  
Another unanswered question is the underlying mechanism of the susceptibility of 
Batf3-/- mice to oral infection with T. gondii. While intraperitoneal infection with T. 
gondii is considered to be “systemic”, oral challenge sets up a local site of infection 
within the small intestine, where T. gondii infects enterocytes in the ileum and also enters 
the submucosal tissue (Barragan and Sibley, 2003). Intestinal CD103+ CD11b- DCs are 
absent in Batf3-/- mice (Edelson et al., 2010), and may serve a critical function in 
protective immunity to oral T. gondii infection. We hypothesize that CD103+ DCs in the 
intestine, similar to CD8α+ DCs in the spleen, are early sensors of T. gondii and may 
function as the initial source of IL-12 at the site of infection. Thus, it remains to be 
determined if CD103+ DCs in the gut express high levels of TLR11, and produce IL-12 in 
response to T. gondii infection in vivo. 
 
IL-12 bypasses the requirement for Batf3 in CD8α+ DC development 
 In the second part of this work, we describe a novel function of IL-12 in 
promoting CD8α+ DC development independently of Batf3. Both exogenous 
administered IL-12, as well as endogenously generated IL-12 in response to T. gondii 
infection, could restore CD8α+ DCs in Batf3-/- mice. Furthermore, IL-12-induced 
restoration of CD8α+ DCs was inhibited by the IFNγ blocking antibody H22. Microarray 
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analysis showed a high degree of similarity between the IL-12-induced CD8α+ DCs in 
Batf3-/- mice and their wild-type counterparts in global gene expression. In addition, 
restored CD8α+ DCs could produce IL-12 in vivo after T. gondii infection. Finally, IL-12 
treatment restored in vivo cross-presentation to necrotic cell-associated antigens as well 
as T. gondii-derived antigens. In summary, IL-12 treatment of Batf3-/- mice rescues the 
CD8α+ DC subset, which is functional for IL-12 production and cross-presentation. 
 A number of studies are currently ongoing to further characterize the mechanism 
by which IL-12 restores CD8α+ DCs, and the functional abilities of these restored cells. 
One possible mechanism is compensation for Batf3 deficiency by another AP-1 family 
member, such as Batf, after IL-12 treatment. Batf/Batf3-double deficient mice are being 
generated to directly answer this question.  
We will also determine if the restored CD8α+ DCs are functional during both T. 
gondii and Listeria monocytogenes infection. In each case, Batf3-/- mice will be treated 
with a single dose of IL-12 to restore CD8α+ DCs, and the mice infected 4-6 days later. If 
restored CD8α+ DCs can respond to T. gondii infection, the survival and parasite burden 
phenotype in Batf3-/- mice will be rescued. As a control for this experiment, we will 
include IL-12p35-/- mice to ensure there is no lasting effect of IL-12 treatment at our 
given time-point, such as increased IFNγ. If there is residual IFNγ after IL-12 treatment, 
both Batf3-/- and IL-12p35-/- mice will be protected, since IFNγ has a number of anti-
parasitic activities (Yap et al., 2006). However, if there is no residual IFNγ, but restored 
CD8α+ DCs are still present and functional, then only the Batf3-/- mice will be protected. 
On the other hand, Batf3-/- mice are resistant to L. monocytogenes infection (BT Edelson, 
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unpublished). Thus, if CD8α+ DCs are still present and functional in IL-12-treated Batf3-
/- mice during L. monocytogenes infection, the resistance will be abrogated. 
 Furthermore, to conclusively address the cross-presentation ability of restored 
CD8α+ DCs, an in vitro cross-presentation assay will be performed. CD8α+ DCs from 
wild-type and IL-12-treated Batf3-/- mice will thus be tested on a per cell basis for cross-
presentation efficiency. Finally, we will investigate the missing peripheral CD103+ DCs 
in Batf3-/- mice to determine if IL-12 treatment also restores these cells.  
 It is unclear what role IL-12 plays in DC subset regulation in wild-type mice 
during physiologic conditions, such as an infection. We hypothesize that IL-12 is 
important in the context of inflammation to expand the main IL-12-producing cell, the 
CD8α+ DC, and further increase IL-12 production. However, our attempts to prove the 
existence of this positive feedback loop using IL-12p35-/- mice did not yield a definitive 
result. Future experiments will address this question using both IL-12-deficient mice, as 
well as IL-12-blocking antibody. 
 In conclusion, we demonstrate a requirement for CD8α+ DC production of IL-12 
during acute T. gondii infection, and describe a novel function of IL-12 in CD8α+ DC 
development in Batf3-/- mice. Future experiments will aim to determine the importance of 
IL-12 in regulating CD8α+ DC homeostasis in inflammatory settings. 
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